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Abstract
Our goal in this research is twofold: to develop clinical performance databases of
cancer patients, and to conduct data mining and machine learning studies on collected
patient records. We use these studies to develop models for predicting cancer patient
medical outcomes. The clinical database is developed in conjunction with surgeons
and oncologists at UMass Memorial Hospital. Aspects of the database design and
representation of patient narrative are discussed here. Current predictive model design
in medical literature is dominated by linear and logistic regression techniques. We seek
to show that novel machine learning methods can perform as well or better than these
traditional techniques.
Our machine learning focus for this thesis is on pancreatic cancer patients. Classifi-
cation and regression prediction targets include patient survival, wellbeing scores, and
disease characteristics. Information research in oncology is often constrained by type
variation, missing attributes, high dimensionality, skewed class distribution, and small
data sets. We compensate for these difficulties using preprocessing, meta-learning, and
other algorithmic methods during data analysis. The predictive accuracy and regres-
sion error of various machine learning models are presented as results, as are t-tests
comparing these to the accuracy of traditional regression methods. In most cases, it is
shown that the novel machine learning prediction methods offer comparable or superior
performance. We conclude with an analysis of results and discussion of future research
possibilities.
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1 Introduction
The pursuit of cancer research has become one of the most important scientific endeavors of
the 21st century. The Cancer Genome Project defines cancer research as “the intense scien-
tific effort to understand the development of cancer and identify potential therapies” [Ins]. In
2004, the American Cancer Society announced that cancer had officially replaced heart dis-
ease as the highest disease-related cause of death for Americans under the age of 85. Over 1.3
million new cancer cases occurred in the United States in 2005, and it is estimated that one
out of every three Americans will be affected by some form of cancer in their lifetime [Soc].
Most major life science fields are already involved extensively in the field of cancer re-
search. Biology and medical science have been an integral part of cancer study since the
time of the Ancient Greeks. However, as technologies and therapies evolve in the mod-
ern era, there is an increasing demand for specialized advances from the field of computer
science. Just a few of computer science’s contributions to cancer research include diagnos-
tic tools, predictive modeling, imaging and data analysis, bioinformatics, medical training
applications, and collaborative research databases. Discoveries from computer science are
already implemented in a wide variety of cancer therapies, including surgery, radiotherapy,
chemotherapy, diagnostic imaging, immunotherapy, and genetic therapy.
Study of clinical performance is one of cancer research’s most important research sub-
jects, as it directly concerns the patient’s wellbeing. Clinical performance refers to a patient’s
response to applied medical therapy. Response factors may include changes in health, pro-
gression of illness, disease pathology, and systemic behaviors of the body. More refined
analysis of clinical performance is always needed, given the frequent complexity and diffi-
culty of cancer treatment. These analyses may include building predictive models for clinical
performance generated using the data mining and machine learning techniques from the field
of computer science.
Our goal in this research is twofold: to develop clinical performance databases of cancer
patients, and to conduct data mining and machine learning studies on the collected patient
1
records. We present a novel database designed by UMass Memorial Medical School on-
cologists for representing highly-detailed clinical performance of breast and gastrointestinal
cancer patients. Machine learning techniques will be applied to the patient contents of this
database to generate a variety of predictive models. The tools and techniques of data mining
and machine learning are ideal for this type of analysis. We present and evaluate models
based on pancreatic cancer patient data for predicting disease characteristics and prognosis
of survival and wellbeing.
This research is a joint effort between the WPI Computer Science Department and UMass
Memorial Medical School. The clinical database is composed of data from patients seen at the
UMass Memorial Department of Surgical Oncology. This project is advised by Prof. Carolina
Ruiz, whose research focus is machine learning and data mining. Prof. George Heineman
of WPI and Prof. Sergio Alvarez of Boston College provided additional computer science
advising. Medical advising is provided by the Surgical Oncology staff at UMass Memorial,
particularly Dr. Giles Whalen and Mary Sullivan NP for the gastrointestinal module, and
Dr. Robert Quinlan for the breast module. A grant provided by UMass Memorial in August
2005 funded this research.
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2 Medical Background
Cancer refers to diseases resulting from uncontrolled cell growth in regions known as neo-
plasms or tumors. A tumor may refer to any distinct mass in a tissue or organ, and its growth
may either be benign or malignant. Malignant tumors are characterized by their ability to
spread to surrounding local tissue (invasion) or distant sites in the body (metastasis). The
malignant tumors discussed in this research are a form of cancer known as carcinoma, or
cancers arising from epithelial cells. Tumor growth may be caused by damage or mutations
to cell DNA from different factors, including hereditary conditions, environmental exposure,
and infectious disease. Chemical or physical agents which trigger cancer-causing DNA mu-
tations are referred to as carcinogens. Symptoms of cancer depend on the site of the body
affected, the nature of the tumor, and metastatic spread of the disease.
Oncology is the branch of medicine which deals with the diagnosis and treatment of ma-
lignant tumors. Various methods exist to treat cancer. Resection is the surgical excision of
tumor growth from bodily tissue. Chemotherapy is the systemic or localized application of
antineoplastic drugs to destroy or retard the development of tumor growth. Radiotherapy
refers to treatments which use irradiation to destroy cancerous cells. Palliation collectively
refers to the methods intended to relieve cancer symptoms rather than effect cure. Pallia-
tive measures may include stenting, anastomosis, feeding tubes, nerve blocks, and various
forms of surgery, chemotherapy, and radiotherapy, as well as other medications for symptom
management. The intention of a resection may be either curative or palliative. Tumor im-
munotherapy is a biological protocol which uses methods such as vaccination to trigger an
immune system response which destroys cancerous cells. Gene counseling is a series of DNA
tests which establish susceptibility of a patient or their family to certain forms of cancer.
An important aspect of patient clinical performance research is quantification of a pa-
tient’s wellbeing. Measurements of wellbeing are important in evaluating treatment response
and qualifications for different forms of care. Throughout the course of their treatment, pa-
tient overall health and performance status may be rated by quality-of-life (QoL) scores
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Score Status
100% Normal, No Complaints, No Signs of Disease
90% Capable of Normal Activity, Few Symptoms or Signs of Disease
80% Normal Activity with Some Difficulty, Some Symptoms or Signs
70% Caring for Self, Not Capable of Normal Activity or Work
60% Requiring Some Help, Can Take Care of Most Personal Requirements
50% Requires Help Often, Requires Frequent Medical Care
40% Disabled, Requires Special Care and Help
30% Severely Disabled, Hospital Admission Indicated but No Risk of Death
20% Very Ill, Urgently Requiring Admission, Requires Treatment
10% Moribund, Rapidly Progressive Fatal Disease Processes
0% Death
Table 1: QoL/Karnofsky Scores
Score Status
0 Asymptomatic
1 Symptomatic but Completely Ambulant
2 Symptomatic, <50% in Bed During the Day
3 Symptomatic, >50% in Bed, but Not Bedbound
4 Bedbound
5 Death
Table 2: ECOG Scores
(also known as Karnofsky scores), which ranges 0-100%, or Eastern Cooperative Oncol-
ogy Group (ECOG) scores, which ranges 0-5. Tables 1 and 2 detail the criteria for these
scores [KB49, OC82]. For the purpose of this thesis, patient wellbeing will be measured
using the ECOG system.
Different factors may be used to describe the nature of tumors. Histology refers to the
microscopic structure of tumor tissue. The behavior and severity of a cancer may vary de-
pending on its histologic composition. Adenocarcinoma is carcinoma which develops within
glandular epithelium which typically behaves in a very malignant fashion. Neuroendocrine
tumors grow in nervous or endocrine tissue. For some cancers, including malignancies of
the pancreas, these neuroendocrine tumors tend to behave in a more indolent fashion than
adenocarcinomas. Cysts refer to closed cavities of glandular epithelium where retained se-
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cretions are accumulated, and may behave in a benign or malignant fashion. Two common
histologic forms of breast cancer are lobular and ductal types. The study of cells at a mi-
croscopic level is referred to as cytology. At the microscopic level, the symptoms of cancer
are often influenced by the growth and penetration of tumors into bodily structures. Lymph
nodes are small bodies along lymphatic vessels which filter bacteria and foreign bodies. The
presence of tumorous tissue within regional lymph nodes is an important prognostic factor
for many types of cancer. The penetration of tumors into vasculature, or blood vessels, can
be an important factor in determining the spread and resectability of the disease.
The American Joint Committee on Cancer (AJCC) maintains a staging system to pro-
vide a unified methodology for describing cancer. Malignant tumors are classified by TNM
staging, which refers to Tumor, Node, and Metastasis. Each parameter is paired with a
number from a discrete range to indicate disease stage. The meaning of these parameters
differs by cancer etiology. T refers to primary tumor size and ranges from 0 to 4 or ’is’ for in
situ growth. N refers to regional lymph node involvement and ranges from 0 to 3. M refers
to metastatis to distant organs and is denoted 0 if absent and 1 if present. Other parameters
may be used to describe cancer. R is used to denote tumor growth on margins of surgically
excised tissue: 0 for clean margins, 1 for microscopic tumor growth, and 2 for gross tumor
growth. L and V (0-1) denote the absence or presence of tumor invasion into lymphatic
vessels and veins. G (1-4) stands for the grade or differentiation between tumor cells and
surrounding normal cells. The criteria for staging depends on the tumor location and his-
tology. Most tumor forms use TNM staging, but not all use the full range. In all staging
systems, a parameter paired with X stands for an unknown or unevaluated quantity [oC04].
A variety of tools are used to diagnose cancer. Serum studies refer to blood tests, which
may include nutritional levels, liver functions, and molecular tumor markers. Biopsy refers to
a small sample of tumor tissue taken to evaluate its histologic composition and malignancy.
Biopsies may be taken in a variety of ways, including fine-needle aspiration (FNA), core-
cutting needle, incisional biopsy, and excisional biopsy. Cancer is frequently diagnosed using
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imaging studies. Quantifying the accuracy and reliability of imaging studies is a crucial
research topic. X-rays are the process of visualizing an internal body image by catching high-
energy photons on photographic film. A computed axial tomography (CT or CAT) creates a
three-dimensional internal view of a patient using a series of sectional x-rays across a common
axis. Ultrasound uses ultrasonic waves to create a sonographic visualization a body’s internal
structure. Endoscopic ultrasound (EUS) is an ultrasound study generated by a thin, flexible
ultrasound probe passed through the gastrointestinal tract. Magnetic resonance imaging
(MRI) uses the magnetic resonance of photons to create a high-contrast density image.
Biopsies are often taken using guidance by imaging studies. Different diagnoses are used
depending on the type and location of cancer [VD93].
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2.1 Pancreatic Cancer Background
Pancreatic cancer remains a challenging disease for physicians, oncologists, and surgeons,
and is the machine learning analytic focus of this thesis. Here, pancreatic cancer is a general
term for cancer of the pancreas and periampullary region. The pancreas is a long gland
which sits behind the stomach and secretes digestive juices into the small intestine and
bloodstream. The periampullary region refers to the area containing the duodenum, distal
common bile duct, and ampulla of Vater. The duodenum refers to the upper part of the
small intestine, which starts from the lower end of the stomach and extends to the jejunum
(middle small intestine). The distal common bile duct is the portion of the excretory passage
close to the duodenum which carries bile from the liver. The ampulla of Vater is a dilation
in the duodenal wall through which the common bile duct and pancreatic duct empty into
the small intestine. Please refer to Figures 1 and 2 [Gra95, Cen].
Tumors of the pancreatic and periampullary region are known for a high degree of mor-
tality and morbidity. This disease stands as the fourth largest cancer killer in the country,
even though it only accounts for 2% of total cancer diagnoses. Approximately 25,000 new
patients are diagnosed with this disease in the United States each year; median survival from
time of diagnosis is six months, with five-year survival rates at 3% [Bre04]. The severity and
treatment of these cancers depend largely on their locations and histologic types. The most
frequently occurring types are adenocarcinomas, which are the most aggressive and have the
highest associated mortality rates. A less common and more indolent form of the disease
are neuroendocrine or islet cell tumors. Intraductal papillary mucinous neoplasms (IPMNs
or IPMT’s) are cystic pancreatic tumors which can progress to cancers.
7
Figure 1: Gray’s Anatomy - Pancreas and Periampullary Region [Gra95]
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Figure 2: Digestive System with Common Bile Duct Illustrated [Cen]
9
Pancreatic cancer typically presents itself through non-specific symptoms, abdominal
pain and painless jaundice being the most frequent. Risk factors include age, smoking,
obesity, diabetes, diets high in meat, chronic pancreatitis, and genetic family history. Di-
agnosis is typically performed using chest x-rays, serum studies, abdominal CT scans, and
endoscopic ultrasound. Imaging studies be used to determine tumor size, regional lymph
note involvement, and distant metastatic spread. Biopsies taken by fine needle aspiration
(FNA) during endoscopic ultrasound can be used to predict tumor histology and malignancy.
Nuclear tumor markers such as CEA and CA19-9, as well as nutritional and liver function
serum levels, can confirm the systemic presence of pancreatic cancer or evaluate its effects. In
preliminary evaluation, approximately 15% of patients are deemed as potentially resectable,
40% as locally advanced/unresectable, and 45% as metastatic or equivocal.
TNM staging for pancreatic cancer determines the treatment course and prognosis of
disease. The T-stage in pancreatic cancer refers to the tumor’s size and penetration into sur-
rounding gastrointestinal anatomy. A simplified version of the AJCC staging criteria [oC04]
is presented in Table 3. Regional lymph node involvement as denoted by N-stage and pres-
ence of metastatis as denoted by M-stage is presented in Tables 4 and 5. Tumor spread in
pancreatic cancer may involve vascular structures, which impacts disease spread and diffi-
culty of resection. Vascular structures which may be invaded include the celiac axis, hepatic
artery, superior mesenteric artery, superior mesenteric vein, inferior vena cava, portal vein,
and splenic vein. If a tumor penetrates a venous structure, then sections of the vein may be
resected. However, arterial penetrations cannot be resected given current medical technol-
ogy, although studies are being done. The microscopic penetration of tumor into a vascular
structure is denoted by V-staging as described above.
The most common surgical procedure to treat pancreatic cancer is a Whipple procedure,
or pancreaticoduodenectomy. The procedure involves removal of the distal half of stomach,
gall bladder, distal common bile duct, head of the pancreas, duodenum, proximal jejunum,
and regional lymph nodes. The remaining anatomy is anastomosed together to reconstruct
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T-Stage Criteria
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor limited to pancreas and measures 2 cm or
less in greatest dimension, without blood vessel involvement
T2 Tumor greater than 2 cm in greatest dimension, still
limited to the pancreas, without involve any blood vessels
T3 Any tumor that extends beyond the pancreas, does not
involve the celiac axis or superior mesenteric artery.
T4 Any tumor that invades the superior mesenteric artery
or the celiac axis (unresectable cancer)
Table 3: Pancreatic Cancer T-Staging
N-Stage Criteria
NX Regional lymph node involvement cannot be assessed
N0 No evidence of regional lymph node involvement
N1 Presence of regional lymph node involvement
Table 4: Pancreatic Cancer N-Staging
M-Stage Criteria
MX Distant metastasis cannot be assessed
M0 No evidence of distant metastasis
M1 Presence of distant metastasis
Table 5: Pancreatic Cancer M-Staging
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a working digestive tract. The pre and post-surgical anatomy of a Whipple procedure are
shown in Figures 3 and 4 [Cli]. The surgical mortality rate of a Whipple procedure is ap-
proximately 5%, 3% in high-volume centers. Resective surgery is usually performed in most
circumstances where possible, as it represents the highest likelihood of complete cure. Rea-
sons not to resect include local tumor spread, involvement of vasculature, distant metastatis,
and patient unwillingness or inability to endure surgery.
Chemotherapy and radiotherapy are frequently applied as pancreatic cancer treatments.
The most common regimens of chemotherapy applied at UMass Memorial are 5-Flurouracil
and Gemcitabine. Cancer therapies may be either adjuvant (applied post-surgery) or neoad-
juvant (applied pre-surgery, frequently in an effort to reduce tumor size). Palliative measures
intended to alleviate but not cure disease include feeding tubes, stenting, gastric bypasses,
nerve blocks, and palliative chemo or radiotherapy. After initial treatment, patients are fol-
lowed at three-month intervals for the first two years, and six-month intervals for two to five
years, and yearly intervals afterwards. Factors monitored during follow-up include disease
status, recurrent symptoms, weight, serum markers, and general wellbeing scores.
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Figure 3: Whipple Procedure - Pre-Surgical Anatomy [Cli]
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Figure 4: Whipple Procedure - Post-Surgical Anatomy [Cli]
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3 Clinical Database Construction
The clinical database is where our patient information is collected. Our database was de-
veloped using Microsoft Access 2003 with Visual Basic scripting and SQL Server for data
storage. It is hoped that these additional cancer modules will be used in future analytic
work. Prof. George Heineman of WPI and [Szo82] provided many useful suggestions in
representing the patient treatment narrative within a software application.
Specific details pertaining to the patient medical factors are too complex to be discussed
here; for those interested, [VD93] provides an accessible discussion of clinical oncology for
both medical and non-medical audiences alike.
3.1 Gastrointestinal Cancer Database
For this project, database modules were developed for six major forms of gastrointestinal
cancer (pancreatic, biliary, esophageal, gastric, colorectal, and hepatocellular). Specific de-
sign of the gastrointestinal cancer modules were based on Dr. Whalen algorithms for patient
treatment. Portions of the table schema and interface were based on earlier work by Tiffany
Wei of UMass Memorial.
In this database, the major elements of patient treatment were decomposed into eight
categories:
• Presentation
• Medical History
• Diagnostic Tests
• Preliminary Outlook
• Treatment
• Surgical Resection Details/Reasons for Not Pursuing Resection
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• Pathology Reports
• Follow-Up
Each of these categories is represented by a table schema within the database. They
are related to a core patient record by a zero-to-many cardinality; this allows for a flexible,
efficient representation of what can often be a very complex clinical narrative.
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3.1.1 Pancreatic Cancer
Figure 5: Pancreatic Cancer Presentation Form
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Figure 6: Pancreatic Cancer Presentation Schema
Figure 7: Pancreatic Cancer Medical History Form
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Figure 8: Pancreatic Cancer Medical History Table Schema
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Figure 9: Pancreatic Cancer Serums Studies Form
Figure 10: Pancreatic Cancer Serums Studies Table Schema
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Figure 11: Pancreatic Cancer Diagnostic Imaging Form
Figure 12: Pancreatic Cancer Diagnostic Imaging Table Schema
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Figure 13: Pancreatic Cancer Endoscopy Studies Form
22
Figure 14: Pancreatic Cancer Endoscopy Studies Table Schema
Figure 15: Pancreatic Cancer Preliminary Outlook Form
Figure 16: Pancreatic Cancer Preliminary Outlook Table Schema
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Figure 17: Pancreatic Cancer Treatment Form
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Figure 18: Pancreatic Cancer Treatment Table Schema
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Figure 19: Pancreatic Cancer Resection Form
Figure 20: Pancreatic Cancer Resection Table Schema
26
Figure 21: Pancreatic Cancer No Resection Form
Figure 22: Pancreatic Cancer No Resection Table Schema
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Figure 23: Pancreatic Cancer Pathology Form
Figure 24: Pancreatic Cancer Pathology Table Schema
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Figure 25: Pancreatic Cancer Follow-Up Form
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Figure 26: Pancreatic Cancer Follow-Up Table Schema
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3.1.2 Hepatocellular Cancer
Figure 27: Hepatocellular Cancer Presentation Form
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Figure 28: Hepatocellular Cancer Presentation Table Schema
Figure 29: Hepatocellular Cancer Medical History Form
32
Figure 30: Hepatocellular Cancer Medical History Table Schema
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Figure 31: Hepatocellular Cancer Serum Studies Form
Figure 32: Hepatocellular Cancer Serum Studies Table Schema
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Figure 33: Hepatocellular Cancer Diagnostic Imaging Form
Figure 34: Hepatocellular Cancer Diagnostic Imaging Table Schema
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Figure 35: Hepatocellular Cancer Preliminary Outlook Form
Figure 36: Hepatocellular Cancer Preliminary Outlook Table Schema
36
Figure 37: Hepatocellular Cancer Treatment Form
Figure 38: Hepatocellular Cancer Treatment Table Schema
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Figure 39: Hepatocellular Cancer Ablation Form
Figure 40: Hepatocellular Cancer Ablation Table Schema
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Figure 41: Hepatocellular Cancer Resection Form
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Figure 42: Hepatocellular Cancer Resection Table Schema
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Figure 43: Hepatocellular Cancer No Resection Form
Figure 44: Hepatocellular Cancer No Resection Table Schema
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Figure 45: Hepatocellular Cancer Pathology Form
Figure 46: Hepatocellular Cancer Pathology Table Schema
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Figure 47: Hepatocellular Cancer Follow-Up Form
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Figure 48: Hepatocellular Cancer Follow-Up Table Schema
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3.1.3 Gall Bladder/Biliary Cancer
Figure 49: Gall Bladder/Biliary Cancer Presentation Form
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Figure 50: Gall Bladder/Biliary Cancer Presentation Table Schema
Figure 51: Gall Bladder/Biliary Cancer Medical History Form
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Figure 52: Gall Bladder/Biliary Cancer Medical History Table Schema
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Figure 53: Gall Bladder/Biliary Cancer Serum Studies Form
Figure 54: Gall Bladder/Biliary Cancer Serum Studies Table Schema
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Figure 55: Gall Bladder/Biliary Cancer Diagnostic Imaging Form
Figure 56: Gall Bladder/Biliary Cancer Diagnostic Imaging Table Schema
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Figure 57: Gall Bladder/Biliary Cancer Preliminary Outlook Form
Figure 58: Gall Bladder/Biliary Cancer Preliminary Outlook Table Schema
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Figure 59: Gall Bladder/Biliary Cancer Treatment Form
Figure 60: Gall Bladder/Biliary Cancer Treatment Table Schema
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Figure 61: Gall Bladder/Biliary Cancer Resection Form
52
Figure 62: Gall Bladder/Biliary Cancer Resection Table Schema
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Figure 63: Gall Bladder/Biliary Cancer No Resection Form
Figure 64: Gall Bladder/Biliary Cancer No Resection Table Schema
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Figure 65: Gall Bladder/Biliary Cancer Pathology Form
Figure 66: Gall Bladder/Biliary Cancer Pathology Table Schema
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Figure 67: Gall Bladder/Biliary Cancer Follow-Up Form
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Figure 68: Gall Bladder/Biliary Cancer Follow-Up Table Schema
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3.1.4 Gastric Cancer
Figure 69: Gastric Cancer Presentation Form
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Figure 70: Gastric Cancer Presentation Table Schema
Figure 71: Gastric Cancer Medical History Form
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Figure 72: Gastric Cancer Medical History Table Schema
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Figure 73: Gastric Cancer Serum Studies Form
Figure 74: Gastric Cancer Serum Studies Table Schema
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Figure 75: Gastric Cancer Diagnostic Imaging Form
Figure 76: Gastric Cancer Diagnostic Imaging Table Schema
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Figure 77: Gastric Cancer Preliminary Outlook Form
Figure 78: Gastric Cancer Preliminary Outlook Table Schema
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Figure 79: Gastric Cancer Treatment Form
Figure 80: Gastric Cancer Treatment Table Schema
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Figure 81: Gastric Cancer Resection Form
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Figure 82: Gastric Cancer Resection Table Schema
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Figure 83: Gastric Cancer No Resection Form
Figure 84: Gastric Cancer No Resection Table Schema
67
Figure 85: Gastric Cancer Pathology Form
Figure 86: Gastric Cancer Pathology Table Schema
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Figure 87: Gastric Cancer Follow-Up Form
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Figure 88: Gastric Cancer Follow-Up Table Schema
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3.1.5 Esophageal Cancer
Figure 89: Esophageal Cancer Presentation Form
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Figure 90: Esophageal Cancer Presentation Table Schema
Figure 91: Esophageal Cancer Medical History Form
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Figure 92: Esophageal Cancer Medical History Table Schema
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Figure 93: Esophageal Cancer Serum Studies Form
Figure 94: Esophageal Cancer Serum Studies Table Schema
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Figure 95: Esophageal Cancer Diagnostic Imaging Form
Figure 96: Esophageal Cancer Diagnostic Imaging Table Schema
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Figure 97: Esophageal Cancer Preliminary Outlook Form
Figure 98: Esophageal Cancer Preliminary Outlook Table Schema
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Figure 99: Esophageal Cancer Treatment Form
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Figure 100: Esophageal Cancer Treatment Table Schema
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Figure 101: Esophageal Cancer Resection Form
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Figure 102: Esophageal Cancer Resection Table Schema
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Figure 103: Esophageal Cancer No Resection Form
Figure 104: Esophageal Cancer No Resection Table Schema
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Figure 105: Esophageal Cancer Pathology Form
Figure 106: Esophageal Cancer Pathology Table Schema
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Figure 107: Esophageal Cancer Follow-Up Form
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Figure 108: Esophageal Cancer Follow-Up Table Schema
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3.1.6 Colorectal Cancer
Figure 109: Colorectal Cancer Presentation Form
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Figure 110: Colorectal Cancer Presentation Table Schema
Figure 111: Colorectal Cancer Medical History Form
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Figure 112: Colorectal Cancer Medical History Table Schema
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Figure 113: Colorectal Cancer Serum Studies Form
Figure 114: Colorectal Cancer Serum Studies Table Schema
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Figure 115: Colorectal Cancer Diagnostic Imaging Form
Figure 116: Colorectal Cancer Diagnostic Imaging Table Schema
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Figure 117: Colorectal Cancer Preliminary Outlook Form
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Figure 118: Colorectal Cancer Preliminary Outlook Table Schema
Figure 119: Colorectal Cancer Treatment Form
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Figure 120: Colorectal Cancer Treatment Table Schema
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Figure 121: Colorectal Cancer Ablation Form
Figure 122: Colorectal Cancer Ablation Table Schema
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Figure 123: Colorectal Cancer Resection Form
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Figure 124: Colorectal Cancer Resection Table Schema
Figure 125: Colorectal Cancer No Resection Form
95
Figure 126: Colorectal Cancer No Resection Table Schema
Figure 127: Colorectal Cancer Pathology Form
Figure 128: Colorectal Cancer Pathology Table Schema
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Figure 129: Colorectal Cancer Follow-Up Form
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Figure 130: Colorectal Cancer Follow-Up Table Schema
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3.2 Breast Cancer Database
The table schema and interface layout was designed with the help of UMass Medical School
oncologists through one-on-one work and efforts of a database committee headed by Dr.
Robert Quinlan.
Figure 131: Breast Cancer Screening Form
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Figure 132: Breast Cancer Screening Table Schema
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Figure 133: Breast Cancer Staging Form
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Figure 134: Breast Cancer Staging Table Schema
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Figure 135: Breast Cancer Resection Form
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Figure 136: Breast Cancer Resection Table Schema
Figure 137: Breast Cancer Chemotherapy Form
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Figure 138: Breast Cancer Chemotherapy Table Schema
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Figure 139: Breast Cancer Radiotherapy Form
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Figure 140: Breast Cancer Radiotherapy Table Schema
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Figure 141: Breast Cancer Metastatic Treatment Form
Figure 142: Breast Cancer Metastatic Treatment Table Schema
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Figure 143: Breast Cancer Follow-Up Form
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Figure 144: Breast Cancer Follow-Up Table Schema
Figure 145: Breast Cancer Pathology Form
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Figure 146: Breast Cancer Pathology Table Schema
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4 Clinical Performance Machine Learning -
Procedure & Design
4.1 Objectives of Analysis
As the pancreatic cancer module was the most developed and populated module within our
database, it was chosen to be the focus of our machine learning analysis. Given the aggres-
sive nature of these tumors, treatment decisions may often be a complex and ambiguous
task, particularly in regard to resective surgery. Physicians seek prediction models to aid
in the application of pancreatic cancer therapies in a clinical setting. Prediction models for
pancreatic cancer clinical factors, particularly survival rates, have been suggested based on
such factors as TNM staging, age, gender, presentation symptoms, medical comorbidities,
tumor histology, and relation of disease to vasculature. The majority of these predictive
models in modern oncology literature are generated by regression algorithms (e.g. linear
regression, logistic regression, and Cox’s proportional hazard model) [Tse04, FS03, SR02].
We have chosen a set of prediction targets for which to develop prediction models. We use
linear and logistic regression algorithms, as well as machine learning classification algorithms
(Bayesian methods, decision trees, k-nearest-neighbor, multi-layer perceptrons, etc.), to gen-
erate prediction models which are novel to pancreatic cancer research. Our hope is that these
novel prediction models may enlightened and improve upon current treatment methods. For
the preparation and analysis of our data, pre-processing algorithms will be used, including
supervised discretization and correlation-based feature selection. Meta-learning algorithms,
such as Bagging and AdaBoostM1, will be used to boost prediction model effectiveness. The
accuracy of these novel prediction models will be statistically compared to models generated
by traditional regression methods. The prediction targets studied will include tumor size,
T-staging, N-staging, vasculature involvement, tumor histology, malignancy, survival rates,
and ECOG scores at 6-month, 9-month, and 12-month follow-up intervals.
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4.2 Patient Data Set
Our study population is composed of pancreatic cancer patients seen over the past three years
at UMass Memorial hospital in Worcester, Massachusetts. Complete screening, treatment,
and follow-up records were retrospectively compiled from the hospital’s Meditech electronic
record system into our clinical database. Supervision by the medical staff was provided
for the interpretation of ambiguous or incomplete records. A total of 91 evaluations for
pancreatic cancer treatment were done between April 2003 and May 2006, representing 87
unique patients.
During these evaluations, all patients were screened for tumor resection using diagnostic
imaging and clinical evaluation. A total of 74 (81%) resections were subsequently performed
with a surgical success rate (complete excision of tumor) of 96%. Radiotherapy was assigned
in 37 (41%) evaluations, chemotherapy in 39 (43%) evaluations, and palliative measures in
11 (12%) evaluations. Among the tumors evaluated, 75 (82%) were deemed potentially re-
sectable, 7 (8%) locally advanced/unresectable, and 9 (10%) metastatic or equivocal. Patient
age at time of enrollment ranged from 28.5 to 85.1, with an average age of 63.9. Among
the patients, 49 (56%) were female. Distribution and availability of this study’s prediction
targets are detailed in Tables 6 through 15.
Our objective of effective data mining was challenged by various aspects of this data
set. Only a relatively small number of patient instances were available for the study, which
is a frequent concern in oncology research. Studies are often constrained by the number of
patients seen at an institution, or the rarity of certain disease etiologies [KBK+97]. However,
the number of patients available here has proved sufficient in other pancreatic cancer stud-
ies [DD04, SR02]. The limited number of patients is made more difficult by the inconsistent
availability of certain prediction targets. Factors such as T-stage, N-stage, tumor size, and
follow-up ECOG scores are not provided for all patients. Unavailability of clinical factors
also extends to many patient attributes.
In an effort to create a detailed clinical database, patient representations in table schemata
113
are highly dimensional. After serializing attributes are removed, approximately 190 columns
of data are processed for each patient instance. Although this creates a very detailed clin-
ical representation of the patient, the attributes vary greatly in importance, accuracy, and
availability, which in turn impacts predictive model accuracy. Data typing also varies–both
nominal and numeric attributes are captured in a patient instance. As many aspects of the
clinical narrative are tracked, from presentation to treatment to follow-up, there are even
some theoretical questions as to whether a collaborative interpretation of these factors may
be the correct approach.
Finally, there is the issue of skewed class distribution in data sets. In pancreatic cancer,
certain values may frequently dominate various clinical factors. For example, in our patient
data set, a large majority of the histologic types are ductal adenocarcinoma, T3 value ac-
counts for 76% of all T-stagings, 82% tumors behave in a malignant fashion, and the majority
of patients do not require a vascular resection. These data patterns lend themselves to pre-
dictive models which underemphasize the importance of correctly predicting non-majority
class values.
In our experimental design, various data mining methods are incorporated to compensate
for these issues. Use of meta-learning algorithms helps compensate for small data sets and
reduces the effect of over-fitting. Supervised discretization creates a uniformly typed set
of attributes. Feature selection algorithms pare highly dimensional groups of attributes to
smaller sets of independently behaving features which are highly correlated to the target
class. Future research will incorporate over-sampling techniques to improve models based
on skewed data sets. These techniques will be discussed more thoroughly in the following
section.
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Value Count
0.0 - 2.0 cm 19
2.0 - 3.2 cm 20
3.2 - 4.8 cm 18
4.8 cm - inf 17
N = 74
Table 6: Tumor Size Distribution
Value Count
T0 1
T1 2
T2 3
T3 39
T4 6
N = 51
Table 7: T-Stage Distribution
Value Count
N0 16
N1 34
N2 1
N = 51
Table 8: N-Stage Distribution
Value Count
True 13
False 61
N = 74
Table 9: Vasculature Involvement Distribution
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Value Count
Adenocarcinoma of Pancreas - NOS 24
Ampullary Adenocarcinoma 9
Benign Cyst 1
Cystadenoma 4
Distal Cholangiocarcinoma 1
Duodenal Adenocarcinoma 2
Ductal Adenocarcinoma of Pancreas 27
IPMN - Benign or CiS 11
MEN-I 1
Mucinous Cystic Neoplasm 1
Neuroendocrine 5
Pseudopapillary Tumor 1
Renal Mets 3
Von Hippel-Lindau Syndrome 1
N = 91
Table 10: Histology Distribution
Value Count
Benign 16
Malignant 75
N = 91
Table 11: Malignancy Distribution
Value Count
0 37
1 27
2 8
N = 68
Table 12: ECOG 6-Month Distribution
Value Count
0 33
1 13
2 7
3 4
N = 57
Table 13: ECOG 9-Month Distribution
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Value Count
0 23
1 12
2 7
3 2
N = 34
Table 14: ECOG 12-Month Distribution
Value Count
0 - 6 mo. 20
6 - 12 mo. 20
12 - inf mo. 20
N = 60
Table 15: Survival Distribution
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4.3 Data Mining and Machine Learning Algorithms Used
The following machine learning algorithms are used in our experiments to generate prediction
models. In creating prediction models, a target may be interpreted as a nominal (categorical)
or numeric class. The interpretation of the prediction target influence what machine learning
algorithms may be applied. Brief descriptions and research citations are provided. All
algorithm executions are run using the Weka machine learning workbench [IW05]. The
debug parameter is set to False for all algorithm executions.
4.3.1 Benchmark Algorithms
These algorithms generate prediction models which are used as performance benchmarks for
our remaining experiments.
• ZeroR - Rudimentary zero-knowledge algorithm used to predict entity classification.
ZeroR models in nominal prediction choose the most frequently occurring target clas-
sification across all available instances. ZeroR models in numeric prediction choose the
average target value of available instances [Mit97].
• Linear Regression - Algorithm which expresses a numeric class as a linear combina-
tion of weighted attributes. The weights of each attribute are calculated based on the
training data. Weights are chosen during model generation such that sum of squares of
differences between the training and prediction instances is minimized. Weka’s imple-
mentation of linear regression uses Akaike criterion for model selection. Weka parame-
ters used are attributeSelectionMethod = M5 method, eliminateColinearAttributes =
True, ridge = 1.0E-8 [Aka74, Dev95].
• Logistic Regression - Works in a similar fashion to linear regression in combining a
weighted set of attributes. Used for nominal targets. For dual-class targets, the lin-
ear model is based on a logit transformation of the target class. Multiple classes ar
generated using pairwise classification. Attribute weights are assigned by maximizing
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log-likelihood of the predictive model. Weka parameters used are maxIts = -1, ridge
= 1.0E-8 [lCvH92].
4.3.2 Classification Algorithms
Classification algorithms are used to generate prediction models for nominal targets and
binned ranges of numeric targets.
• OneR - Rudimentary algorithm which uses single-attribute models to predict entity
classification. Also known as 1R or Learn-One-Rule. OneR is known for reasonable
accuracy in characterizing experimental data in spite of its relative simplicity. Weka
parameters used are minBucketSize = 6 [Mit97].
• J48 - A Java implementation of the C4.5 decision tree learning algorithm. C4.5 is an
evolution of the basic ID3 decision tree algorithm which accounts for missing values,
continuous attributes, pruning of decision trees, and rule derivation. Weka parameters
used are binarySplits = False, confidenceFactor = 0.25, minNumObj = 2, numFolds =
3, reducedErrorPruning = False, saveInstanceData = False, seed = 1, subtreeRaising
= True, unpruned = False, useLaplace = False [IW05, Qui93].
• Locally Weighted Learning - Instance-based prediction model which weights training
instances in relation to their distance to the test instance. Closer instances are assigned
higher weight and more relevance to the prediction. Can be combined with most
classifier algorithms. Locally weighted learning plus Naive Bayes is known to be very
effective on small data sets and can outperform independent executions of Naive Bayes
and k-nearest-neighbor. Weka parameters used are KNN = -1, classifier = NaiveBayes,
dontNormalize = False, weightingKernel = 0 [FHP03, AMS97].
• K-Nearest-Neighbor - An instance-based model which produces a classification by
calculating the k-closest known members in instance space. Assumes attributes are
equally important and normalized. Space between attribute values is calculated using
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Euclidean distance. Value of k is determined by cross-validation. Weka parameters
used are KNN = varies by experiment, crossValidate = False, distanceWeighting =
No distance weighting, meanSquared = False, noNormalization = False, windowSize
= 0 [AKA91].
• Naive Bayes - The NaiveBayes algorithm is a predictive classifier based on probabil-
ity models rooted in Bayes Theorem. It assumes statistical independence amongst
the attributes in predicting a target classification. NaiveBayes offers surprising accu-
racy in characterizing data from a variety of domains despite its statistical simplicity.
Weka parameters used are useKernelEstimator = False, useSupervisedDiscretization
= False [Mit97].
• Bayes Net - Bayesian networks are directed acyclic graphs which represent complex
statistical relationships for attributes of an entity. Bayesian net predictors construct
a graph probability model for classification using a specified network evaluator and
network-space search function. Weka parameters used are BIFFile = null, estimator =
SimpleEstimator -A 0.5, searchAlgorithm = K2 -P [varies by experiment], useADTree
= False [IW05].
4.3.3 Regression Algorithms
Regression algorithms are used to generate prediction models for numeric classes.
• M5P - A Java implementation of the M5 algorithm. M5 is a decision tree predictor
which builds model trees based on information gain measures. These model trees split
the data into test outcomes, which are used to produce a set of multivariate linear
regression models. Weka allows both regression trees and model trees to be produced as
output. Weka parameters used are buildRegressionTree = False, minNumInstances =
4.0, saveInstances = False, unpruned = False, useUnsmoothed = False [IW05, Qui92].
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• Multi-layer Perceptron - A neural network which uses backpropagation to train network
connection weights. The number of layers for each model are determined during the
experiment. Attributes and numeric classes are normalized during execution. Weka
parameters used are GUI = false, autoBuild = False, decay = False, hiddenLayers =
varies by experiment, learningRate = 0.3, momentum = 0.2, nominalToBinaryFilter
= True, normalizeAttributes = True, normalizeNumericClass = True, randomSeed =
0, reset = True, trainingTime = 500, validationSetSize = 0, validationThreshold =
20 [IW05].
• Radial Basis Function Network - A variation on the multi-layer perceptron which is
implemented by a feedforward network. Computation at each hidden node is performed
using k-means computation of distance space. The output, or activation, of the node
depends on its distance from the input instance–closer distance generates stronger
activation. Similarity measures are calculated using a Gaussian activation function.
Network output is a linear combination of hidden node outputs. Weka parameters
used are clusteringSeed = 1, maxIts = -1, minStdDev = 0.1, numClusters = 2, ridge
= 1.0E-8 [MD89].
4.3.4 Data Preprocessing Algorithms
Data preprocessing methods allow us to achieve various representations of the clinical patient
data when conducting experiments. These can potentially improve accuracy of the prediction
models generated.
• Discretization - Numeric attribute data may be discretized to form nominal attributes.
Discretization is either a supervised or unsupervised process. Unsupervised discretiza-
tion proceeds by simply binning data into specified ranges. Supervised discretization
bins attributes relative to changes in the target classification. Here, we measure changes
in target classification using the Minimum Descriptive Length (MDL) principle. Weka
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parameters used for supervised discretization are attributeIndices = first-last, invert-
Selection = False, makeBinary = False, useBetterEncoding = False, useKononenko =
False [FI93].
• Feature Selection - Correlation-based Feature Selection (CFS) is an attribute-selection
algorithm used for eliminating noisy and redundant features in data sets. Attributes
are selected using heuristic search of correlation measurements. Optimal attribute sets
exhibit high correlation to their target class and low correlation to other attributes.
Feature selection is useful for paring down high-dimensional data. Weka parameters
used are evaluator = CfsSubsetEval, search = BestFirst -D 1 -N 5 [Hal98].
4.3.5 Meta-Learning Algorithm
Meta-learning algorithms are used to improve the accuracy of our machine learning tests.
Meta-learning refines models to be more robust against noisy data and less susceptible to
over-fitting, particularly when dealing with small data sets.
• AdaBoostM1 - AdaBoostM1 works by incrementally running classifiers on samples of
test data and combining them into an aggregate model. Each individual or weak clas-
sifier contributes to the aggregate model in proportion to its accuracy. After each
iteration, test data is reweighted based on incorrect aggregate classifications. This
boosts the emphasis of misclassified instances, which refines future weak classifier ex-
ecutions. Weka parameters used are classifier = varies by experiment, numIterations
= 10, seed = 1, useResampling = False, weightThreshold = 100 [FS96].
• Bagging - Bagging (or Bootstrap Aggregating) works similarly to Boosting by com-
bining the results of multiple classifiers into an aggregate model. Multiple prediction
models are trained and aggregated using equal-sized resamples from the training data.
Bagging is known to be particularly useful when small changes in data can imply large
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changes in classification. Weka parameters used are bagSizePercent = 100, calcOutOf-
Bag = False, classifier = varies by experiment, numIterations = 10, seed = 1 [Bre96].
• Stacking - The Stacking algorithm is a meta-learner which reduces individual bias by
combining multiple classifier types. First, a series of general classifiers generate level-0
prediction models from a given test set. Data assembled from the output of these
models is combined by another classifier to generate a level-1 prediction model. Weka
parameters used are classifiers = varies by experiment, metaClassifier = DecisionS-
tump, numFolds = 10, seed = 1 [Wol90].
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4.4 Experimental Design
Clinical prediction models are generated using classification for nominal targets and regres-
sion for numeric targets. The experiment names of nominal targets (which also include
binned numeric ranges) are listed in Table 16. The experiment names of numeric targets are
listed in Table 17.
Each experiment is performed using 10-fold cross-validation. As some of these experi-
ments are probabilistic in nature, they are repeated over 10 iterations with random seeding.
Performance of classification models are evaluated by calculating the average accuracy (per-
centage correct) classifications across these iterations. Regression models are evaluated by
calculating r-squared values (Equation 1), which define percentage of response variability
accounted for by the prediction model [Dev95].
r2 =
ESS
TSS
(1)
ESS stands for Explained Sum of Squares (Equation 2). It stands for the sum of squares
of the differences of the predicted independent variable (yˆi) within the regression model and
the overall average of actual independent variables, or grand mean (y¯). TSS stands for Total
Sum of Squares (Equation 3). It stands for the sum of squares of the differences of the actual
independent variable (yi) and the grand mean.
ESS =
n∑
i=1
(yˆi − y¯)
2 (2)
TSS =
n∑
i=1
(yi − y¯)
2 (3)
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Experiment Prediction Target
C1 Tumor Size (binned)
C2 T-Stage
C3 N-Stage
C4 Vasculature Involvement
C5 Histology
C6 Malignancy
C7 ECOG 6-Month
C8 ECOG 9-Month
C9 ECOG 12-Month
C10 Survival (binned)
Table 16: Classification Experiments
Experiment Prediction Target
R1 Tumor Size
R2 ECOG 6-Month
R3 ECOG 9-Month
R4 ECOG 12-Month
R5 Survival
Table 17: Regression Experiments
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Category Symbol Algorithm
Rule-based
ZR ZeroR
1R OneR
Decision Trees J48 C4.5 Decision Trees
Lazy Evaluators
IB1 K-Nearest-Neighbor k=1
IB2 K-Nearest-Neighbor k=2
IB3 K-Nearest-Neighbor k=3
LWL Locally Weighted Learning w/ Naive Bayes
Bayesian Methods
BN1 Bayes Net p=1
BN2 Bayes Net p=2
BN3 Bayes Net p=3
NVB Naive Bayes
Regression LGR Logistic Regression
Table 18: Classification Algorithms
4.4.1 Classification Tests
The classification algorithms used and their associated parameters are described in Table 18.
Each classification algorithm was repeated using AdaBoostM1 (AB1) and Bagging (BG)
meta-learners.
Four data sets (A-D) based on each prediction target (C1-C10) were created from the
clinical database. Each data set was first anonymized and stripped of serializing attributes
(date of admission, medical record number, etc.). Numeric targets (tumor size, survival,
etc.) were binned into equal frequency numeric ranges so to be compatible with nominal
classification. Classification target ranges, including numeric bins, are described in Table 19.
Preprocessing methods were applied to each data set as described in Table 20. Supervised
discretization was used to create uniform nominal attributes, which occasionally produces
more accurate experimental results [IW05]. Attribute selection was used to pare down the
high dimensionality of the original data sets. Frequently, attribute selection produces more
accurate prediction models. It was also useful in generating a medically novel set of highly-
correlated, independently behaving attributes for the clinical factor in question.
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Clinical Factors - Nominal Categories
Tumor Size 0 - 2.0 cm, 2.0 - 3.2 cm, 3.2 - 4.8 cm, 4.8 cm - inf
T-Stage TX - T4
N-Stage NX - N2
Vasculature Involvement Yes, No
Histology
Adenocarcinoma of Pancreas - NOS,
Ampullary Adenocarcinoma, Ductal Adeno of Pancreas,
Neuroendocrine, Duodenal Adenocarcinoma, Distal
Cholangiocarcinoma, Renal Mets, Cystadenoma,
IPMN - Benign or CiS, Benign Cyst
Malignancy Malignant, Benign
ECOG 6-Month 0 - 4 (Ref. Table 2)
ECOG 9-Month 0 - 4 (Ref. Table 2)
ECOG 12-Month 0 - 4 (Ref. Table 2)
Survival Rate 0 - 7.0 mo., 7.0 - 16.8 mo., 16.8 - inf
Table 19: Classification Target Values
Data Set Pre-processing Filters (ref. Section 4.3.4)
A
Class Discretization: Discrete target classes are
required for classification algorithms. Nominal target classes
are naturally discrete. Numeric target are discretized via
unsupervised equal-frequency binning.
B
Supervised Attributes Discretization: Instance attributes
are discretized via MDL method. Derived from Data Set A.
C
Correlation-based Feature Selection: Attribute subsets are chosen
based on the CFS method. Derived from Data Set A.
D
Correlation-based Feature Selection and Supervised Discretization:
Uses both MDL discretization and CFS attribute
selection. Derived from Data Set B.
Table 20: Classification Data Sets
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Category Symbol Algorithm
Rule-based ZR ZeroR
Decision Trees
M5M M5P w/ Model Trees
M5R M5P w/ Regression Trees
Neural Network
MLP Multi-layer Perceptron
RBF Radial Basis Function
Regression LNG Linear Regression
Table 21: Regression Algorithms
Clinical Factors - Numeric Ranges
Tumor Size 0.0 - 11.0 cm
ECOG 6-Month 0 - 2
ECOG 9-Month 0 - 3
ECOG 12-Month 0 - 3
Survival Rate 1.4 - 44.2 mo.
Table 22: Regression Experiments
4.4.2 Regression Tests
The regression algorithms used and their associated parameters are described in Table 21.
Regression target numeric ranges are described in Table 22. Each regression run is repeated
using Bagging (BG) meta-learners (AdaBoostM1 is unable to handle numeric targets). Ad-
ditionally, the Stacking (STK) meta-learner is used to combine the M5P decision trees, RBF
networks and linear regression models.
Two data sets (E-F) based on each prediction target (R1-R5) were created from the
clinical database. Data sets were anonymized and serializing attributes removed as with
classification tests. Attribute selection preprocessing methods were applied as described in
Table 23. Supervised discretization filtering was not applied as it requires a nominal target
class [FI93].
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Data Set Pre-processing Filters (ref. Section 4.3.4)
E
Unaltered Data Set: Uses original
instance data with numeric target classes.
F
Correlation-based Feature Selection: Attribute subsets are chosen
based on the CFS method. Derived from Data Set E.
Table 23: Regression Data Sets
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5 Clinical Performance Machine Learning -
Results & Analysis
For each experiment, we present result sets and graphs for basic algorithm executions and
executions using meta-learners. For classification tests, we conduct t-tests of performance of
algorithms versus logistic regression. For regression tests, t-tests are performed of algorithm
performance versus linear regression. All t-tests are performed with significance α = .05
[Dev95]. T-test results are denoted with ’=’ for statistically equivalent performance, ’+’ for
superior performance, and ’−’ for inferior performance.
5.1 C1 - Tumor Size
For the tumor size tests among N=74 patients, we predict tumor size of 4 numeric bins
which contain roughly equal numbers of patients. Distribute of target values is shown in
Table 6. Classification accuracy for tumor size prediction generally ranges from 40% to 55%.
The majority of algorithms performed comparably to logistic regression via t-testing. Data
sets with supervised discretization and attribute selection generally produced more accurate
results. No statistically significant change was seen when meta-learning was introduced.
Figure 147: Tumor Size - Accuracy Results (Percentage)
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Figure 148: Tumor Size - Accuracy Results (Percentage) - AdaBoostM1
Figure 149: Tumor Size - Accuracy Results (Percentage) - Bagging
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Figure 150: Tumor Size - Results Graph
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Figure 151: Tumor Size - Results Graph - AdaBoostM1
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Figure 152: Tumor Size - Results Graph - Bagging
Figure 153: Tumor Size - T-Test vs. Logistic Regression
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Figure 154: Tumor Size - T-Test vs. Logistic Regression - AdaBoostM1
Figure 155: Tumor Size - T-Test vs. Logistic Regression - Bagging
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5.2 C2 - T-Stage
For the t-staging tests among N=51 patients, we predict t-stage of 5 classes which are dom-
inated by value T3 (approx. 75% of patients). Distribute of target values is shown in
Table 7. Classification accuracy for t-size prediction generally ranges from 70% to 80%.
Unfortunately, analysis of the associated confusion matrices show that prediction dominates
for the majority T3 class and under-predicts the remaining values. The majority of algo-
rithms in A and B data sets performed better than logistic regression via t-testing–this seems
due more to logistic regression’s unusually poor performance for these sets. Data sets with
supervised discretization and attribute selection generally produced results of comparable
accuracy. No statistically significant change was seen when meta-learning was introduced.
Figure 156: T-Stage - Accuracy Results (Percentage)
Figure 157: T-Stage - Accuracy Results (Percentage) - AdaBoostM1
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Figure 158: T-Stage - Accuracy Results (Percentage) - Bagging
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Figure 159: T-Stage - Results Graph
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Figure 160: T-Stage - Results Graph - AdaBoostM1
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Figure 161: T-Stage - Results Graph - Bagging
Figure 162: T-Stage - T-Test vs. Logistic Regression
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Figure 163: T-Stage - T-Test vs. Logistic Regression - AdaBoostM1
Figure 164: T-Stage - T-Test vs. Logistic Regression - Bagging
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5.3 C3 - N-Stage
For the n-staging tests among N=51 patients, we predict n-stage of 3 classes which are dom-
inated by value N1 (approx. 2:1 ratio to remaining values). Distribute of target values is
shown in Table 8. Classification accuracy for n-size prediction generally ranges from 55%
to 85%. The majority of algorithms in the original A data sets performed better than lo-
gistic regression via t-testing–particulary k-nearest-neighbor, locally-weighted-learning, and
Bayesian nets. For the remaining data sets, algorithms generally performed equally. Data
sets with supervised discretization and attribute selection generally produced results with
higher accuracy. No statistically significant change was seen when meta-learning was intro-
duced.
Figure 165: N-Stage - Accuracy Results (Percentage)
Figure 166: N-Stage - Accuracy Results (Percentage) - AdaBoostM1
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Figure 167: N-Stage - Accuracy Results (Percentage) - Bagging
Classification - N-Stage
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Figure 168: N-Stage - Results Graph
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Figure 169: N-Stage - Results Graph - AdaBoostM1
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Classification -  N-Stage - Bagging
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Figure 170: N-Stage - Results Graph - Bagging
Figure 171: N-Stage - T-Test vs. Logistic Regression
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Figure 172: N-Stage - T-Test vs. Logistic Regression - AdaBoostM1
Figure 173: N-Stage - T-Test vs. Logistic Regression - Bagging
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5.4 C4 - Vascular Involvement
For the vascular involvement tests among N=74 patients, we predict the values of 2 classes
which are dominated by ’false’ values (approx. 80% of patients). Distribute of target values
is shown in Table 9. Classification accuracy for vascular involvement prediction generally
ranges from 75% to 85%. Analysis of the associated confusion matrices show that prediction
dominates for the majority ’false’ class and under-predicts the remaining values. Data sets
with supervised discretization and attribute selection generally produced results with higher
accuracy. No statistically significant change was seen when meta-learning was introduced.
Figure 174: Vascular Involvement - Accuracy Results (Percentage)
Figure 175: Vascular Involvement - Accuracy Results (Percentage) - AdaBoostM1
Figure 176: Vascular Involvement - Accuracy Results (Percentage) - Bagging
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Figure 177: Vascular Involvement - Results Graph
147
Classification -  Vasculature - 
AdaBoostM1
70.00
72.00
74.00
76.00
78.00
80.00
82.00
84.00
86.00
88.00
90.00
L
G
R
1
R
.A
B
1
J4
8
.A
B
1
IB
1
.A
B
1
IB
2
.A
B
1
IB
3
.A
B
1
L
W
L
.A
B
1
N
V
B
.A
B
1
B
N
1
.A
B
1
B
N
2
.A
B
1
B
N
3
.A
B
1
Classification Method
A
c
c
u
ra
c
y A
B
C
D
Figure 178: Vascular Involvement - Results Graph - AdaBoostM1
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Figure 179: Vascular Involvement - Results Graph - Bagging
Figure 180: Vascular Involvement - T-Test vs. Logistic Regression
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Figure 181: Vascular Involvement - T-Test vs. Logistic Regression - AdaBoostM1
Figure 182: Vascular Involvement - T-Test vs. Logistic Regression - Bagging
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5.5 C5 - Histology
For the histology tests among N=91 patients, we predict value of 14 target class values
which are dominated by ’Adenocarcinoma of Pancreas - NOS’ and ’Ductal Adenocarcinoma
of Pancreas’ (these histology values dominate approximately 55% of instances). Distribute
of target values is shown in Table 10. Classification accuracy for histology prediction models
generally range from 35% to 55%. Analysis of the associated confusion matrices show that
prediction dominates for the majority classes and ’IPMN - Benign or CiS’ while under-
predicting the remaining values. Data sets with supervised discretization and attribute
selection combined with Bayesian net predictions generally produced results with higher
accuracy than logistic regression via t-tests. Remaining machine learning algorithms were
comparable to logistic regression accuracy in most cases. No statistically significant change
was seen when meta-learning was introduced. High-performance models based on histology
classification are presented in Section 6.1.
Figure 183: Histology - Accuracy Results (Percentage)
Figure 184: Histology - Accuracy Results (Percentage) - AdaBoostM1
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Figure 185: Histology - Accuracy Results (Percentage) - Bagging
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Figure 186: Histology - Results Graph
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Figure 187: Histology - Results Graph - AdaBoostM1
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Classification -  Histology - Bagging
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Figure 188: Histology - Results Graph - Bagging
Figure 189: Histology - T-Test vs. Logistic Regression
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Figure 190: Histology - T-Test vs. Logistic Regression - AdaBoostM1
Figure 191: Histology - T-Test vs. Logistic Regression - Bagging
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5.6 C6 - Malignancy
For the malignancy tests among N=91 patients, we predict value of 2 classes which are
dominated by ’Malignant’ values (approx. 80% of cases). Distribute of target values is shown
in Table 11. Classification accuracy for malignancy prediction generally ranges from 70% to
85%. Analysis of the associated confusion matrices show a reasonable spread between the
majority classes and minority values. Data sets with supervised discretization and attribute
selection generally produced results with higher accuracy. Classification algorithms were
t-test comparable to logistic regression accuracy in most cases. No statistically significant
change was seen when meta-learning was introduced.
Figure 192: Malignancy - Accuracy Results (Percentage)
Figure 193: Malignancy - Accuracy Results (Percentage) - AdaBoostM1
Figure 194: Malignancy - Accuracy Results (Percentage) - Bagging
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Figure 195: Malignancy - Results Graph
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Figure 196: Malignancy - Results Graph - AdaBoostM1
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Classification -  Malignancy - Bagging
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Figure 197: Malignancy - Results Graph - Bagging
Figure 198: Malignancy - T-Test vs. Logistic Regression
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Figure 199: Malignancy - T-Test vs. Logistic Regression - AdaBoostM1
Figure 200: Malignancy - T-Test vs. Logistic Regression - Bagging
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5.7 C7 - ECOG 6-Month
For ECOG 6-Month tests among N=72 patients, we predict value of 3 classes which are rea-
sonably well-distributed (ECOG values represented are those available among instances.).
Distribution of target values is shown in Table 12. Classification accuracy for ECOG pre-
diction generally ranges from 55% to 75%. Data sets with supervised discretization and at-
tribute selection generally produced results with higher accuracy. Classification algorithms
were t-test comparable to logistic regression accuracy in most cases. No statistically signifi-
cant change was seen when meta-learning was introduced.
Figure 201: ECOG 6-Month - Accuracy Results (Percentage)
Figure 202: ECOG 6-Month - Accuracy Results (Percentage) - AdaBoostM1
Figure 203: ECOG 6-Month - Accuracy Results (Percentage) - Bagging
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Figure 204: ECOG 6-Month - Results Graph
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Figure 205: ECOG 6-Month - Results Graph - AdaBoostM1
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Figure 206: ECOG 6-Month - Results Graph - Bagging
Figure 207: ECOG 6-Month - T-Test vs. Logistic Regression
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Figure 208: ECOG 6-Month - T-Test vs. Logistic Regression - AdaBoostM1
Figure 209: ECOG 6-Month - T-Test vs. Logistic Regression - Bagging
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5.8 C8 - ECOG 9-Month
For ECOG 9-Month tests among N=57 patients, we predict value of 4 classes which are
reasonably well-distributed (ECOG values represented are those available among instances.).
Distribute of target values is shown in Table 13. Classification accuracy for ECOG prediction
generally ranges from 45% to 70%. Data sets with supervised discretization and attribute
selection generally produced results with higher accuracy. Classification algorithms were
t-test comparable to logistic regression accuracy in most cases. No statistically significant
change was seen when meta-learning was introduced.
Figure 210: ECOG 9-Month - Accuracy Results (Percentage)
Figure 211: ECOG 9-Month - Accuracy Results (Percentage) - AdaBoostM1
Figure 212: ECOG 9-Month - Accuracy Results (Percentage) - Bagging
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Figure 213: ECOG 9-Month - Results Graph
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Figure 214: ECOG 9-Month - Results Graph - AdaBoostM1
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Figure 215: ECOG 9-Month - Results Graph - Bagging
Figure 216: ECOG 9-Month - T-Test vs. Logistic Regression
169
Figure 217: ECOG 9-Month - T-Test vs. Logistic Regression - AdaBoostM1
Figure 218: ECOG 9-Month - T-Test vs. Logistic Regression - Bagging
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5.9 C9 - ECOG 12-Month
For ECOG 12-Month tests among N=44 patients, we predict value of 4 classes which are
reasonable well distributed (ECOG values represented are those available among instances.).
Distribute of target values is shown in Table 14. Classification accuracy for ECOG pre-
diction generally ranges from 35% to 55%. The majority of algorithms in A and B data
sets performed better than logistic regression via t-testing; again, this seems due more to
logistic regression’s poor performance on these sets. Data sets with supervised discretization
and attribute selection generally produced results with equivalent accuracy. Classification
algorithms in C and D sets were t-test comparable to logistic regression accuracy in most
cases. No statistically significant change was seen when meta-learning was introduced.
Figure 219: ECOG 12-Month - Accuracy Results (Percentage)
Figure 220: ECOG 12-Month - Accuracy Results (Percentage) - AdaBoostM1
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Figure 221: ECOG 12-Month - Accuracy Results (Percentage) - Bagging
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Figure 222: ECOG 12-Month - Results Graph
172
Classification - ECOG 12-Month - 
AdaBoostM1
20.00
25.00
30.00
35.00
40.00
45.00
50.00
55.00
60.00
L
G
R
1
R
.A
B
1
J4
8
.A
B
1
IB
1
.A
B
1
IB
2
.A
B
1
IB
3
.A
B
1
L
W
L
.A
B
1
N
V
B
.A
B
1
B
N
1
.A
B
1
B
N
2
.A
B
1
B
N
3
.A
B
1
Classification Method
A
c
c
u
ra
c
y
A
B
C
D
Figure 223: ECOG 12-Month - Results Graph - AdaBoostM1
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Figure 224: ECOG 12-Month - Results Graph - Bagging
Figure 225: ECOG 12-Month - T-Test vs. Logistic Regression
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Figure 226: ECOG 12-Month - T-Test vs. Logistic Regression - AdaBoostM1
Figure 227: ECOG 12-Month - T-Test vs. Logistic Regression - Bagging
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5.10 C10 - Survival
For survival tests among N=60 patients, we predict value of 4 numeric ranges which are
evenly distributed between bins. Distribute of target values is shown in Table 15. Classifi-
cation accuracy for survival prediction generally ranges from 40% to 60%. Naive Bayes and
Bayesian nets in A and B data sets performed better than logistic regression via t-testing–a
notable result. Data sets with supervised discretization and attribute selection generally
produced results with higher accuracy. Remaining machine learning algorithms were t-test
comparable to logistic regression accuracy in most cases. No statistically significant change
was seen when meta-learning was introduced.
Figure 228: Survival - Accuracy Results (Percentage)
Figure 229: Survival - Accuracy Results (Percentage) - AdaBoostM1
Figure 230: Survival - Accuracy Results (Percentage) - Bagging
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Figure 231: Survival - Results Graph
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Figure 232: Survival - Results Graph - AdaBoostM1
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Figure 233: Survival - Results Graph - Bagging
Figure 234: Survival - T-Test vs. Logistic Regression
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Figure 235: Survival - T-Test vs. Logistic Regression - AdaBoostM1
Figure 236: Survival - T-Test vs. Logistic Regression - Bagging
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5.11 R1 - Tumor Size
For tumor-size regression tests among N=74 patients, we predict numeric values ranging
from 0 to 11 cm. Distribute of target values is shown in Table 6. Regression r-squared values
for survival prediction range from .00 to .45. Linear regression and M5 model trees per-
formed best. Data sets with attribute selection generally produced results with comparable
r-squared values. Remaining machine learning algorithms were t-test inferior to linear re-
gression accuracy in most cases. Meta-learning introduced statistically superior performance
in multi-layer perceptrons when compared to linear regression performance.
Figure 237: Tumor Size - R-Squared Results
Figure 238: Tumor Size - R-Squared Results - AdaBoostM1
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Figure 239: Tumor Size - Regression Results Graph
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Figure 240: Tumor Size - Regression Results Graph - Bagging and Stacking
Figure 241: Tumor Size - T-Test vs. Linear Regression
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Figure 242: Tumor Size - T-Test vs. Linear Regression - Meta-learners
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5.12 R2 - ECOG 6-Month
For ECOG 6-Month regression tests among N=72 patients, we predict numeric values ranging
from 0 to 2 (ECOG values represented are those available among instances.). Distribute
of target values is shown in Table 12. Regression r-squared values for ECOG prediction
range from .00 to .27. Multi-layer perceptrons and RFB networks perform best, particularly
with meta-learning on set F. Data sets with attribute selection generally produced results
with higher r-squared values. Remaining machine learning algorithms were t-test inferior
to linear regression accuracy in most cases. Meta-learning introduced statistically superior
performance in multi-layer perceptrons, M5 model trees, and linear regression with bagging
when compared to standard linear regression performance. High-performance models based
on ECOG 6-Month regression are presented in Section 6.3.
Figure 243: ECOG 6-Month - R-Squared Results
Figure 244: ECOG 6-Month - R-Squared Results - AdaBoostM1
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Figure 245: ECOG 6-Month - Regression Results Graph
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Figure 246: ECOG 6-Month - Regression Results Graph - Bagging and Stacking
Figure 247: ECOG 6-Month - T-Test vs. Linear Regression
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Figure 248: ECOG 6-Month - T-Test vs. Linear Regression - Meta-learners
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5.13 R3 - ECOG 9-Month
For ECOG 9-Month regression tests among N=57 patients, we predict numeric values rang-
ing from 0 to 3 (ECOG values represented are those available among instances.). Distribute
of target values is shown in Table 13. Regression r-squared values for ECOG prediction
range from .00 to .25. Multi-layer perceptrons and RFB networks perform best, particularly
on set E. Data sets with attribute selection generally produced results with higher r-squared
values. Remaining machine learning algorithms were t-test comparable or inferior to linear
regression accuracy in most cases. Meta-learning introduced statistically superior perfor-
mance in most tested models when compared to standard linear regression performance.
High-performance models based on ECOG 9-Month regression are presented in Section 6.4.
Figure 249: ECOG 9-Month - R-Squared Results
Figure 250: ECOG 9-Month - R-Squared Results - AdaBoostM1
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Regression -  ECOG 9-Month
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Figure 251: ECOG 9-Month - Regression Results Graph
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Regression -  ECOG 9-Month - Meta-
Learners
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Figure 252: ECOG 9-Month - Regression Results Graph - Bagging and Stacking
Figure 253: ECOG 9-Month - T-Test vs. Linear Regression
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Figure 254: ECOG 9-Month - T-Test vs. Linear Regression - Meta-learners
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5.14 R4 - ECOG 12-Month
For ECOG 12-Month regression tests among N=44 patients, we predict numeric values rang-
ing from 0 to 3 (ECOG values represented are those available among instances.). Distribute
of target values is shown in Table 14. Regression r-squared values for ECOG prediction range
from .00 to .28. Data sets with attribute selection generally produced results with higher
r-squared values. Remaining machine learning algorithms were t-test comparable or inferior
to linear regression accuracy in most cases. Meta-learning introduced statistically superior
performance in multi-layer perceptrons on the data set E when compared to standard linear
regression performance.
Figure 255: ECOG 12-Month - R-Squared Results
Figure 256: ECOG 12-Month - R-Squared Results - AdaBoostM1
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Regression - ECOG 12-Month
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Figure 257: ECOG 12-Month - Regression Results Graph
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Regression - ECOG 12-Month - Meta-
Learners
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Figure 258: ECOG 12-Month - Regression Results Graph - Bagging and Stacking
Figure 259: ECOG 12-Month - T-Test vs. Linear Regression
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Figure 260: ECOG 12-Month - T-Test vs. Linear Regression - Meta-learners
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5.15 R5 - Survival
For survival regression tests among N=60 patients, we predict numeric values ranging from
0.9 to 29.3 months. Distributions of target values is shown in Table 15. Regression r-squared
values for survival prediction range from .00 to .28. Multi-layer perceptrons and linear re-
gression with bagging performed generally better than linear regression, particularly on set
E. Data sets with attribute selection generally produced results with higher r-squared values
for meta-learning tests. Remaining machine learning algorithms had varied t-test accura-
cies when compared to linear regression. Meta-learning introduced instances of statistically
inferior performance on both data sets.
Figure 261: Survival - R-Squared Results
Figure 262: Survival - R-Squared Results - AdaBoostM1
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Regression - Survival
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Figure 263: Survival - Regression Results Graph
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Regression -  Survival - Meta-Learners
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Figure 264: Survival - Regression Results Graph - Bagging and Stacking
Figure 265: Survival - T-Test vs. Linear Regression
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Figure 266: Survival - T-Test vs. Linear Regression - Meta-learners
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6 High-Performance Predictive Models
Several of the high-performance machine learning models are described in this section. Two
models from the classification experiments and two from the regression experiments are
demonstrated. Each of these models outperform traditional regression methods via statistical
tests. Each model also exhibits interesting structural characteristics, both in their internal
design and the feature-selected attribute sets used to generate them. Verbatim Weka output
of these models follows each section.
6.1 Classification - Histology - Data Set C - Bayesian Net 2-Parent
Shown here is a Bayesian Net 2-Parent classifier with high predictive accuracy for majority
target class values. This model is taken from the C5 experiments in Section 5.5. Histology
prediction is difficult given the wide variety of categorical possibilities (14 types are repre-
sented here). Additionally, certain histology types are only rarely represented in the clinical
setting (MEN-I, pseudopapillary tumors, renal mets). As accurate prediction across all types
is difficult, we seek instead to demonstrate models which can predict some of the more fre-
quently occurring histologic values, including adenocarcinomas, neuroendocrine tumors, and
IMPNs.
A graphical representation of this Bayes Net model is demonstrated in Figures 267
and 268. Classification accuracy for this particular Bayes Net model is 50.55%. For the three
most frequently occurring histologic types, ’Adenocarcinoma of Pancreas - NOS’, ’Ductal
Adenocarcinoma of Pancreas’, and ’IPMN - Benign or CiS’, the predictive accuracy of this
model is 79.03%. The Confusion matrix illustrated in Figure 269 illustrates the model’s
predictive accuracy for different histologic values, with the three majority histologic values
shown boxed.
Experimental iterations of this data set with other Bayesian methods show that the ac-
curacy can be pushed even higher. Naive Bayes classification retains the highest experiment
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accuracy at 56.07% (ref. Figure 183), although the Bayesian Net shown here exhibits a
much more interesting probability structure. Each node on the Bayesian Net reflects the
joint probability distribution for its related attribute as determined by the attribute values
of its parent nodes. These probability distributions are determined by the comparative fre-
quencies of attribute values within the data sets. Examples of these distributions are shown
in Figure 270.
Feature-selection generated a 24 attribute subset for data sets C and D in these experi-
ments. The field names and their explanations are listed in Table 24. Generally, experimental
accuracy was much higher for feature-selected data sets. As this entire subset consists of cat-
egorical attributes, supervised discretization induces no change to the result set. Therefore,
no experimental variation exists on models generated from data set C or D.
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Field Description
PresumptiveDx Presumptive Diagnosis
SxWtloss Presentation - Weight Loss
SxJaun Presentation - Jaundice
SxNau Presentation - Nausea
SxFati Presentation - Fatigue
SxPru Presentation - Pruritis
SxOT Presentation - Other
CxDiab Comorbidities - Diabetes
CTNodeOmit CT - Nodal Omission
EUSVascOmit EUS - Vascular Omission
EUSPortal EUS - Portal Vein Involvement
EUSNoNode EUS - No Nodal Involvement
EUSStagingT EUS - T Staging
EUSCyto EUS - Cytology
TxLap Treatment - Laparoscopy
TxRadia Treatment - Radiotherapy
TxChemo Treatment - Chemotherapy
TxChemoGem Treatment - Chemotherapy - Gemcitabine
ResPxType Resection - Procedure Type
ResTransfusion Resection - Transfusion
ResPOCourse Resection - Postoperative Course
ResPathN Resection - Pathology N-Stage
SurOncName Surgical Oncologist
RadOncName Radiation Oncologist
Table 24: Histology Feature-Selected Attribute Subset
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Figure 267: Classification - Histology - Data Set C - Bayesian Net 2-Parent
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Figure 268: Classification - Histology - Data Set C - Bayesian Net 2-Parent (continued)
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Figure 269: Classification - Histology - Data Set C - Confusion Matrix
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Figure 270: Classification - Histology - Data Set C - Joint Probability Distribution Examples
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Weka Output:
=== Run information ===
Scheme: weka.classifiers.bayes.BayesNet -D -Q weka.classifiers.bayes.
net.search.local.K2 -- -P 2 -E weka.classifiers.bayes.net.
estimate.SimpleEstimator -- -A 0.5
Relation: Book1-weka.filters.supervised.attribute.AttributeSelection-
Eweka.attributeSelection.CfsSubsetEval-Sweka
.attributeSelection.BestFirst -D 1 -N 5
Instances: 91
Attributes: 25
PresumptiveDx
SxWtloss
SxJaun
SxNau
SxFati
SxPru
SxOT
CxDiab
CTNodeOmit
EUSVascOmit
EUSPortal
EUSNoNode
EUSStagingT
EUSCyto
TxLap
TxRadia
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TxChemo
TxChemoGem
ResPxType
ResTransfusion
ResPOCourse
ResPathN
SurOncName
RadOncName
Histology
Test mode: 10-fold cross-validation
=== Classifier model (full training set) ===
Bayes Network Classifier
not using ADTree
#attributes=25 #classindex=24
Network structure (nodes followed by parents)
PresumptiveDx(6): Histology
SxWtloss(2): Histology
SxJaun(2): Histology
SxNau(2): Histology
SxFati(2): Histology
SxPru(2): Histology SxJaun
SxOT(2): Histology
CxDiab(2): Histology SxNau
CTNodeOmit(2): Histology SxPru
EUSVascOmit(2): Histology SxOT
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EUSPortal(2): Histology
EUSNoNode(2): Histology PresumptiveDx
EUSStagingT(5): Histology EUSPortal
EUSCyto(7): Histology
TxLap(2): Histology SxJaun
TxRadia(2): Histology EUSStagingT
TxChemo(2): Histology TxRadia
TxChemoGem(2): Histology TxChemo
ResPxType(7): Histology
ResTransfusion(2): Histology CxDiab
ResPOCourse(2): Histology CTNodeOmit
ResPathN(3): Histology
SurOncName(3): Histology EUSCyto
RadOncName(6): Histology
Histology(14):
LogScore Bayes: -1735.470575102397
LogScore BDeu: -232.372454610241
LogScore MDL: -5005.723116036344
LogScore ENTROPY: -2418.745189048893
LogScore AIC: -3565.745189048918
Time taken to build model: 0.08 seconds
=== Stratified cross-validation ===
=== Summary ===
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Correctly Classified Instances 46 50.5495 %
Incorrectly Classified Instances 45 49.4505 %
Kappa statistic 0.3721
Mean absolute error 0.0767
Root mean squared error 0.2312
Relative absolute error 64.7016 %
Root relative squared error 95.6473 %
Total Number of Instances 91
=== Detailed Accuracy By Class ===
TP Rate FP Rate Precision Recall F-Measure Class
0.5 0.194 0.48 0.5 0.49
Adenocarcinoma_of_Pancreas/NOS
0.444 0.037 0.571 0.444 0.5
Ampullary_Adenocarcinoma
0.667 0.234 0.545 0.667 0.6
Ductal_Adeno_of_Pancreas
0.4 0.047 0.333 0.4 0.364
Neuroendocrine_(Islet_Cell)
0 0 0 0 0
Von_Hippel-Lindau_Syndrome
0 0.011 0 0 0
Duodenal_Adenocarcinoma
0 0 0 0 0
Distal_Cholangiocarcinoma
0 0.011 0 0 0
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Renal_Mets
0.25 0.034 0.25 0.25 0.25
Cystadenoma
0 0 0 0 0
MEN-I
0 0 0 0 0
Pseudopapillary_Tumor
0.818 0.063 0.643 0.818 0.72
IPMN/IPMT_-_Benign_or_CiS
0 0 0 0 0
Mucinous_Cystic_Neoplasm
0 0 0 0 0
Benign_Cyst
=== Confusion Matrix ===
a b c d e f g h i j k l m n <-- classified as
12 2 9 1 0 0 0 0 0 0 0 0 0 0 | a = Adenocarcinoma_of_Pan
4 4 1 0 0 0 0 0 0 0 0 0 0 0 | b = Ampullary_Adenocarcinoma
8 0 18 0 0 0 0 0 0 0 0 1 0 0 | c = Ductal_Adeno_of_Pancreas
1 0 1 2 0 0 0 1 0 0 0 0 0 0 | d = Neuroendocrine_(Islet)
0 0 0 1 0 0 0 0 0 0 0 0 0 0 | e = Von_Hippel-Lindau_Syn
0 1 1 0 0 0 0 0 0 0 0 0 0 0 | f = Duodenal_Adenocarcinoma
0 0 0 0 0 1 0 0 0 0 0 0 0 0 | g = Distal_Cholangiocarcinoma
0 0 0 1 0 0 0 0 1 0 0 1 0 0 | h = Renal_Mets
0 0 1 0 0 0 0 0 1 0 0 2 0 0 | i = Cystadenoma
0 0 0 0 0 0 0 0 0 0 0 1 0 0 | j = MEN-I
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0 0 0 0 0 0 0 0 1 0 0 0 0 0 | k = Pseudopapillary_Tumor
0 0 1 1 0 0 0 0 0 0 0 9 0 0 | l = IPMN/IPMT_-_Benign_or_CiS
0 0 1 0 0 0 0 0 0 0 0 0 0 0 | m = Mucinous_Cystic_Neoplasm
0 0 0 0 0 0 0 0 1 0 0 0 0 0 | n = Benign_Cyst
213
6.2 Classification - Survival - Data Set C - Bayesian Net 2-Parent
Here we have a highly accurate Bayesian Net 2-Parent classifier for survival. This model
is taken from the C10 experiments in Section 5.10. Survival prediction is one of the most
important topics in oncology research, and is subject of many other research papers (ref. Sec-
tion 7). As many of these papers use traditional regression methods for survival prediction,
it is particularly important here to demonstrate higher performance of novel methods.
A graphical representation of this Bayes Net model is illustrated in Figures 271 and 272.
Overall accuracy for this model is rated 60.00%, as compared to average logistic regression
performance 42.50% (ref. Figure 228). The accuracy of 60.00% for this single generation of
the model exceeds the average iterated performance of the models in C10, which means it
outperforms logistic regression via t-testing. There is fairly even coverage across predictions
of different survival categories, as shown via the Confusion Matrix in Figure 273.
An interesting feature of this model is the 19 attribute subset chosen via feature-selection.
The attributes chosen by feature-selection here contain many elements (diabetes, smok-
ing history, prior chemotherapy treatments, need for palliative measures, etc.) which are
known to be highly important in traditional medical assessment of pancreatic cancer sur-
vival rates [VD93]. The descriptions of these attribute fields are shown in Table 25. This
selection of biologically-correlated attributes makes a strong argument for the medical ap-
plicability of this model.
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Field Description
PresumptiveDx Presumptive Diagnosis
SxSatiety Presentation - Early Satiety
SxOT Presentation - Other
CxDiabDiet Comorbidities - Diabetes Diet Controlled
CxPriorCancerChemo Comorbidities - Prior Chemo Treatment
SHCigarette Social History - Cigarettes
PTCDx PTC Diagnosis
EUSDx EUS Diagnosis
EUSSMV EUS - SMV Involvement
EUSNoNode EUS - No Nodal Involvement
Histology Histology
PreOutlook Preliminary Outlook
TxChemoIri Treatment - Chemotherapy - Irinotecan
TxChemoTax Treatment - Chemotherapy - Taxol
TxPal Treatment - Palliation
TxPalStens Treatment - Palliation - Stenting
ResPOPulmComp Resection - Postoperative Course - Pulmonary Complications
NoResNoHandle No Resection - Patient Can’t Handle
SurOncName Surgical Oncologist
Table 25: Survival Feature-Selected Attribute Subset
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Figure 271: Classification - Survival - Data Set C - Bayesian Net 2-Parent
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Figure 272: Classification - Survival - Data Set C - Bayesian Net 2-Parent (continued)
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Figure 273: Classification - Survival - Data Set C - Confusion Matrix
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Weka Output:
=== Run information ===
Scheme: weka.classifiers.bayes.BayesNet -D -Q weka.classifiers
.bayes.net.search.local.K2 -- -P 2 -E weka.classifiers
.bayes.net.estimate.SimpleEstimator -- -A 0.5
Relation: Book1-weka.filters.unsupervised.attribute.Discretize-
F-B3-M-1.0-R191-weka.filters.unsupervised.attribute.
Remove-R184-weka.filters.supervised.attribute.
AttributeSelection-Eweka.attributeSelection
.CfsSubsetEval-Sweka.attributeSelection.BestFirst -D 1 -N 5
Instances: 60
Attributes: 20
PresumptiveDx
SxSatiety
SxOT
CxDiabDiet
CxPriorCancerChemo
SHCigarette
PTCDx
EUSDx
EUSSMV
EUSNoNode
Histology
PreOutlook
TxChemoIri
TxChemoTax
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TxPal
TxPalStens
ResPOPulmComp
NoResNoHandle
SurOncName
Longev
Test mode: 10-fold cross-validation
=== Classifier model (full training set) ===
Bayes Network Classifier
not using ADTree
#attributes=20 #classindex=19
Network structure (nodes followed by parents)
PresumptiveDx(6): Longev
SxSatiety(2): Longev
SxOT(2): Longev
CxDiabDiet(2): Longev
CxPriorCancerChemo(2): Longev
SHCigarette(2): Longev SxSatiety
PTCDx(2): Longev
EUSDx(2): Longev
EUSSMV(2): Longev
EUSNoNode(2): Longev PTCDx
Histology(11): Longev PresumptiveDx
PreOutlook(3): Longev EUSSMV
TxChemoIri(2): Longev EUSDx
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TxChemoTax(2): Longev
TxPal(2): Longev PreOutlook
TxPalStens(2): Longev TxPal
ResPOPulmComp(2): Longev PTCDx
NoResNoHandle(2): Longev TxPal
SurOncName(3): Longev CxDiabDiet
Longev(3):
LogScore Bayes: -648.3033238760419
LogScore BDeu: -199.86101028520844
LogScore MDL: -1466.702725061748
LogScore ENTROPY: -873.0227635395436
LogScore AIC: -1163.0227635395436
Time taken to build model: 0 seconds
=== Stratified cross-validation ===
=== Summary ===
Correctly Classified Instances 36 60 %
Incorrectly Classified Instances 24 40 %
Kappa statistic 0.4
Mean absolute error 0.3055
Root mean squared error 0.4237
Relative absolute error 68.7481 %
Root relative squared error 89.8773 %
Total Number of Instances 60
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=== Detailed Accuracy By Class ===
TP Rate FP Rate Precision Recall F-Measure Class
0.7 0.2 0.636 0.7 0.667 ’(-inf-5.753425]’
0.55 0.2 0.579 0.55 0.564 ’(5.753425-11.769863]’
0.55 0.2 0.579 0.55 0.564 ’(11.769863-inf)’
=== Confusion Matrix ===
a b c <-- classified as
14 3 3 | a = ’(-inf-5.753425]’
4 11 5 | b = ’(5.753425-11.769863]’
4 5 11 | c = ’(11.769863-inf)’
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6.3 Regression - ECOG 6-Month - Data Set F - Linear Regression
w/ Bagging
Here we have a highly accurate Linear Regression w/ Bagging regressor for 6-Month ECOG
scores. This model is taken from the R2 experiments in Section 5.12. This is one of the
first experiments where meta-learning affects a statistical improvement to a model. The
r-squared value for this model is 0.32, as opposed to 0.26 for standard linear regression, a
statistically significant improvement via t-testing. This is also one of the first experiments
where machine learning successfully amplifies a traditional predictive regression.
Figure 274 illustrates the Bagging ’committee’ which constitutes this model. Each com-
mittee member is trained on an N/10 resample of the data set. Training on the resample
produces a unique linear regression equation for each member. Each equation uses different
coefficients and combinations of attributes from the feature-selected data set. When evaluat-
ing a new instance, each member in the committee evaluates and ’votes’ on a possible value
for 6-Month ECOG. The votes are weighted equally by the model, and an aggregate ECOG
prediction is produced. Refer to Section 4.3.5 or [Bre96] for further details on Bagging.
As with most experiments, feature-selected data sets in 6-Month ECOG generally pro-
duced more accurate results. Feature-selection generated a 17 attribute subset for data sets F
in these experiments. The field names and their explanations are listed in Table 26. Interest-
ing, the majority of these fields involve of chemo regimen and details pertaining to whether
a patient underwent resection. These are interesting results, considering that many of these
treatment decisions are made directly regarding a patient’s potential wellbeing performance.
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Field Description
SxChola Presentation - Cholangitis
SxBC Presentation - Biliary Colic
CxDiab Comorbidities - Diabetes
CxPriorCancerChemo Comorbidities - Prior Chemo Treatment
EUSDx EUS Diagnosis
EUSSMVClass EUS - SMV Involvement Class
EUSCeliacNode EUS - Celiac Nodal Involvement
ERCPStentType ERCP Stent Type
TxChemoAva Treatment - Chemotherapy - Avastin
TxChemoCap Treatment - Chemotherapy - Capecitabine
TxChemoTax Treatment - Chemotherapy - Taxol
ResOrgans Resection - Additional Organs
ResPOAbdominal Resection - Postoperative Course - Abdominal Collection
ResPOPulmComp Resection - Postoperative Course - Pulmonary Complications
NoResNoHandle No Resection - Patient Can’t Handle
NoResRefused No Resection - Patient Refused Treatment
NoResPVInvolve No Resection - Portal Vein Involvement
Table 26: ECOG 6-Month Feature-Selected Attribute Subset
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?
ECOG
(Bagging Committee 
Votes Weighted Equally)
0.7708 * CxDiab=TRUE + 
0.7257 * EUSDx=FALSE + 
1.4554 * EUSSMVClass=Encased + 
1.0454 * ResPOPulmComp=FALSE + 
-0.7265 * NoResNoHandle=TRUE + 
0.9548 * NoResRefused=TRUE + 
1.6817 * NoResPVInvolve=TRUE +  
-1.4986
0.8263 * CxDiab=TRUE + 
0.8083 * EUSDx=FALSE + 
1.7504 * EUSCeliacNode=TRUE + 
0.8035 * ERCPStentType=Metal + 
0.6628 * ResPOPulmComp=FALSE + 
0.6595 * NoResPVInvolve=TRUE + 
-0.5322 
0.6748 * CxDiab=TRUE + 
0.7406 * EUSDx=FALSE + 
0.4859 * ResPOPulmComp=FALSE + 
0.8273 * NoResPVInvolve=TRUE + 
-0.0964 
0.6175 * CxDiab=TRUE + 
0.6021 * EUSDx=FALSE + 
1.3825 * EUSSMVClass=Encased + 
1.556  * EUSCeliacNode=TRUE + 
0.5224 * ResOrgans=spleen + 
0.7066 * ResPOPulmComp=FALSE + 
1.0307 * NoResRefused=TRUE + 
-1.2459 
0.9979 * SxChola=TRUE + 
0.683  * CxDiab=TRUE + 
0.7269 * EUSDx=FALSE + 
1.4165 * EUSSMVClass=Encased + 
0.6263 * NoResRefused=TRUE + 
0.5182 * NoResPVInvolve=TRUE + 
-0.1991 
0.6933 * CxDiab=TRUE + 
0.6812 * EUSDx=FALSE + 
1.6045 * EUSCeliacNode=TRUE + 
0.7885 * NoResPVInvolve=TRUE + 
0.3955 
0.7232 * CxDiab=TRUE + 
0.7302 * EUSDx=FALSE + 
1.5916 * EUSCeliacNode=TRUE + 
0.8539 * ERCPStentType=Metal + 
0.5216 * ResOrgans=spleen + 
0.6263 * ResPOPulmComp=FALSE + 
0.9463 * NoResPVInvolve=TRUE + 
-0.8171
0.8249 * SxChola=TRUE + 
0.7269 * CxDiab=TRUE + 
0.6689 * EUSDx=FALSE + 
1.3587 * EUSSMVClass=Encased + 
1.7183 * EUSCeliacNode=TRUE + 
0.6451 * ResPOPulmComp=FALSE + 
0.471  * NoResRefused=TRUE + 
0.6194 * NoResPVInvolve=TRUE + 
-0.8164
1.2688 * SxChola=TRUE + 
0.6268 * CxDiab=TRUE + 
0.514  * EUSDx=FALSE + 
1.3384 * EUSSMVClass=Encased +
1.561  * EUSCeliacNode=TRUE + 
0.4906 * NoResRefused=TRUE + 
0.1044
1.0084 * CxDiab=TRUE + 
0.6853 * EUSDx=FALSE + 
0.9238 * EUSSMVClass=Encased + 
1.6886 * EUSCeliacNode=TRUE + 
0.5635 * ResPOPulmComp=FALSE + 
0.7205 * NoResPVInvolve=TRUE + 
-0.4369
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
N/10 Resample
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Weka Output:
=== Run information ===
Scheme: weka.classifiers.meta.Bagging -P 100 -S 1 -I 10 -W
weka.classifiers
.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation: Book1-weka.filters.supervised.attribute.AttributeSelection
-Eweka.attributeSelection.CfsSubsetEval-Sweka.attribute
Selection.BestFirst -D 1 -N 5
Instances: 72
Attributes: 18
SxChola
SxBC
CxDiab
CxPriorCancerChemo
EUSDx
EUSSMVClass
EUSCeliacNode
ERCPStentType
TxChemoAVA
TxChemoCap
TxChemoTax
ResOrgans
ResPOAbdominal
ResPOPulmComp
NoResNoHandle
NoResRefused
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NoResPVInvolve
ECOG
Test mode: 10-fold cross-validation
=== Classifier model (full training set) ===
All the base classifiers:
Linear Regression Model
ECOG =
1.0084 * CxDiab=TRUE +
0.6853 * EUSDx=FALSE +
0.9238 * EUSSMVClass=Encased +
1.6886 * EUSCeliacNode=TRUE +
0.5635 * ResPOPulmComp=FALSE +
0.7205 * NoResPVInvolve=TRUE +
-0.4369
Linear Regression Model
ECOG =
0.8263 * CxDiab=TRUE +
227
0.8083 * EUSDx=FALSE +
1.7504 * EUSCeliacNode=TRUE +
0.8035 * ERCPStentType=Metal +
0.6628 * ResPOPulmComp=FALSE +
0.6595 * NoResPVInvolve=TRUE +
-0.5322
Linear Regression Model
ECOG =
0.7708 * CxDiab=TRUE +
0.7257 * EUSDx=FALSE +
1.4554 * EUSSMVClass=Encased +
1.0454 * ResPOPulmComp=FALSE +
-0.7265 * NoResNoHandle=TRUE +
0.9548 * NoResRefused=TRUE +
1.6817 * NoResPVInvolve=TRUE +
-1.4986
Linear Regression Model
ECOG =
0.6748 * CxDiab=TRUE +
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0.7406 * EUSDx=FALSE +
0.4859 * ResPOPulmComp=FALSE +
0.8273 * NoResPVInvolve=TRUE +
-0.0964
Linear Regression Model
ECOG =
1.2688 * SxChola=TRUE +
0.6268 * CxDiab=TRUE +
0.514 * EUSDx=FALSE +
1.3384 * EUSSMVClass=Encased +
1.561 * EUSCeliacNode=TRUE +
0.4906 * NoResRefused=TRUE +
0.1044
Linear Regression Model
ECOG =
0.6175 * CxDiab=TRUE +
0.6021 * EUSDx=FALSE +
1.3825 * EUSSMVClass=Encased +
1.556 * EUSCeliacNode=TRUE +
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0.5224 * ResOrgans=spleen +
0.7066 * ResPOPulmComp=FALSE +
1.0307 * NoResRefused=TRUE +
-1.2459
Linear Regression Model
ECOG =
0.8249 * SxChola=TRUE +
0.7269 * CxDiab=TRUE +
0.6689 * EUSDx=FALSE +
1.3587 * EUSSMVClass=Encased +
1.7183 * EUSCeliacNode=TRUE +
0.6451 * ResPOPulmComp=FALSE +
0.471 * NoResRefused=TRUE +
0.6194 * NoResPVInvolve=TRUE +
-0.8164
Linear Regression Model
ECOG =
0.9979 * SxChola=TRUE +
0.683 * CxDiab=TRUE +
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0.7269 * EUSDx=FALSE +
1.4165 * EUSSMVClass=Encased +
0.6263 * NoResRefused=TRUE +
0.5182 * NoResPVInvolve=TRUE +
-0.1991
Linear Regression Model
ECOG =
0.6933 * CxDiab=TRUE +
0.6812 * EUSDx=FALSE +
1.6045 * EUSCeliacNode=TRUE +
0.7885 * NoResPVInvolve=TRUE +
0.3955
Linear Regression Model
ECOG =
0.7232 * CxDiab=TRUE +
0.7302 * EUSDx=FALSE +
1.5916 * EUSCeliacNode=TRUE +
0.8539 * ERCPStentType=Metal +
0.5216 * ResOrgans=spleen +
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0.6263 * ResPOPulmComp=FALSE +
0.9463 * NoResPVInvolve=TRUE +
-0.8171
Time taken to build model: 0.11 seconds
=== Cross-validation ===
=== Summary ===
Correlation coefficient 0.5706
Mean absolute error 0.4522
Root mean squared error 0.5616
Relative absolute error 72.7155 %
Root relative squared error 81.3339 %
Total Number of Instances 72
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6.4 Regression - ECOG 9-Month - Data Set F - Multi-layer Per-
ceptron w/ 2 Hidden Layers
Here we have a highly accurate Multi-layer Perceptron regressor for 9-Month ECOG scores.
This model is taken from the R3 experiments in Section 5.13. The r-squared value for this
model is 0.16, as opposed to 0.04 for standard linear regression, a statistically significant
improvement via t-testing. Multi-layer perceptrons exhibited high r-squared values for many
of the regression experiments. They are generally known in medical data mining for high
accuracy, but it is difficult to discern from their internal structure how their decisions are
produced [KK95].
Figure 275 shows the network layout of this particular regressor. Weights are conditioned
via backpropagation on the training sets. Two hidden layers are used, with a learning weight
of 0.3 and momentum of 0.2. For new instances, input nodes pass attribute values through
the two trained hidden layers, which are aggregated down to produce a ECOG 9-Month
prediction. Following the MLP figure is Weka output showing the trained weights on each
network connection.
Feature-selected data sets in 9-Month ECOG generally produced more accurate results.
Feature-selection generated a 19 attribute subset for data sets F in these experiments. The
field names and their explanations are listed in Table 27. As with 6-Month ECOG, the
majority of these fields involve chemo regimen and details pertaining the patient’s resection.
It may be interesting future work to examine whether there is research precedence that these
factors significantly affect wellbeing performance.
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Field Description
SxChola Presentation - Cholangitis
SxBack Presentation - Back Pain
SxDyspha Presentation - Dysphasia
CxDiabDiet Comorbidities - Diabetes Diet Control
CxHyper Comorbidities - Hypertension
CxPriorCancerChemo Comorbidities - Prior Chemo Treatment
CXRDx Chest X-Ray Diagnosis
EUSSMVClass EUS - SMV Involvement Class
EUSPortal EUS - Portal Vein Involvement
EUSPortalClass EUS - Portal Vein Involvement Class
TxChemoAva Treatment - Chemotherapy - Avastin
TxChemoIri Treatment - Chemotherapy - Irinotecan
TxChemoLeu Treatment - Chemotherapy - Leukovorin
TxChemoTax Treatment - Chemotherapy - Taxol
ResTFFP Resection - Transfusion - Fresh Frozen Plasma
ResPOLeak Resection - Postoperative Course - Leak
ResPOAbdominal Resection - Postoperative Course - Abdominal Collection
ResPOPulmComp Resection - Postoperative Course - Pulmonary Complications
ResPathR Resection - Pathology R-Stage
Table 27: ECOG 9-Month Feature-Selected Attribute Subset
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Figure 275: Regression - ECOG 9-Month - Data Set F - Multi-layer Perceptron w/ 2 Hidden
Layers
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Weka Output:
=== Run information ===
Scheme: weka.classifiers.functions.MultilayerPerceptron -L 0.3 -M 0.2
-N 500 -V 0 -S 0 -E 20 -H 2
Relation: Book1-weka.filters.supervised.attribute.AttributeSelection-
Eweka.attributeSelection.CfsSubsetEval-Sweka.
attributeSelection.BestFirst -D 1 -N 5
Instances: 72
Attributes: 18
SxChola
SxBC
CxDiab
CxPriorCancerChemo
EUSDx
EUSSMVClass
EUSCeliacNode
ERCPStentType
TxChemoAVA
TxChemoCap
TxChemoTax
ResOrgans
ResPOAbdominal
ResPOPulmComp
NoResNoHandle
NoResRefused
NoResPVInvolve
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ECOG
Test mode: 10-fold cross-validation
=== Classifier model (full training set) ===
Linear Node 0
Inputs Weights
Threshold -0.27907681180500077
Node 1 -0.6689299459785472
Node 2 2.0634974138324895
Sigmoid Node 1
Inputs Weights
Threshold 0.2161565560886697
Attrib SxChola -0.8240512834848186
Attrib SxBC 0.9719889319602957
Attrib CxDiab 2.4018587825692728
Attrib CxPriorCancerChemo 1.5612434307033178
Attrib EUSDx -1.7402535693664936
Attrib EUSSMVClass -2.380758092011916
Attrib EUSCeliacNode -2.2846632584637074
Attrib ERCPStentType 0.27077130269695104
Attrib TxChemoAVA 1.6004461214131707
Attrib TxChemoCap 1.0846704053365328
Attrib TxChemoTax 1.3085182989378599
Attrib ResOrgans=spleen -3.775846082844799
Attrib ResOrgans=duodenum_preserving -2.308761590318322
Attrib ResOrgans=pylorus-sparing -1.0989356680294642
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Attrib ResPOAbdominal 1.7485222222375152
Attrib ResPOPulmComp 4.995927948745733
Attrib NoResNoHandle -0.8438995490964636
Attrib NoResRefused -1.1648150708131346
Attrib NoResPVInvolve -1.9970562590263103
Sigmoid Node 2
Inputs Weights
Threshold 0.01931248644125251
Attrib SxChola 1.3618203056809814
Attrib SxBC -9.480039587078225E-4
Attrib CxDiab -2.3505528703455143
Attrib CxPriorCancerChemo -0.8645973811683567
Attrib EUSDx 2.3745261715454515
Attrib EUSSMVClass 3.5097969956607966
Attrib EUSCeliacNode 2.617837343077885
Attrib ERCPStentType 0.8113622216035797
Attrib TxChemoAVA -0.5206862062795482
Attrib TxChemoCap 0.12298147304095629
Attrib TxChemoTax -0.40371463564664195
Attrib ResOrgans=spleen 0.8047396124851516
Attrib ResOrgans=duodenum_preserving -0.27889286068420516
Attrib ResOrgans=pylorus-sparing -0.20715130545850244
Attrib ResPOAbdominal -0.16035164493704002
Attrib ResPOPulmComp -2.2285130411821803
Attrib NoResNoHandle -0.29341318666906574
Attrib NoResRefused 0.5048077573826775
Attrib NoResPVInvolve 2.006560027984653
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Class
Input
Node 0
Time taken to build model: 0.27 seconds
=== Cross-validation ===
=== Summary ===
Correlation coefficient 0.4798
Mean absolute error 0.5168
Root mean squared error 0.655
Relative absolute error 83.1096 %
Root relative squared error 94.8561 %
Total Number of Instances 72
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7 Related Work
A significant amount of work in medical diagnosis using machine learning has come from
the University of Ljubljana, Slovenia, under Prof. Igor Kononenko. [KK95] provides an
excellent overview of the medical applicability of machine learning techniques, and presents
the advantages and disadvantages of different algorithmic approaches. [Kon93] covers similar
ground and presents inductive and Bayesian learning technical for medical analysis in more
detail. The techniques discussed in his works have been applied in many medical fields,
including pathology, urology, cardiology, and neuropsychology. Work done in [KBK+97]
applies specifically to oncology, using machine learning to predict the survival time of patients
with thyroid carcinoma. The algorithmic focus of this work deals primarily with regression,
Assistant decision trees, and Bayesian techniques. We present a broader variety of predictive
algorithms in our oncological analysis, and examine different ways to improve algorithmic
accuracy, including feature selection and meta-learning.
Machine learning techniques, particularly regression methods, are used commonly in
medical literature. [FS03] uses multivariate logistic regression and Cox’s proportional hazard
model to show that liver metastatis and peritoneal implants are major predictive factors in
pancreatic cancer survival. [SR02] contends, using Kaplan-Meier survival analysis, that
tumor grading, angioinvasion and perineural invasion are not sufficient pancreatic cancer
survival factors. Dr. Murray Brennan makes prolific use of machine learning techniques in his
research, and presents in [Bre04] a predictive nomogram for pancreatic cancer survival. Dr.
Jennifer Tseng in [Tse04] uses multivariate regression to study survival rates of pancreatic
cancer who undergo superior mesenteric or portal vein resections. Our research differs in our
broader variety of predictive techniques, and that we look additionally at patient wellbeing
and tumor pathology characteristics.
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8 Conclusions and Future Work
This thesis set out with two goals–to develop detailed clinical databases of cancer patients,
and to conduct machine learning studies on the patient data. With the help of medical pro-
fessionals at UMass Memorial Hospital, we were able to successfully build clinical databases
of seven different cancer forms which can represent the broad narrative of patient treatment.
This database was tested by accumulating about a hundred detailed pancreatic cancer pa-
tient records. Using this data, we tested a variety of novel machine learning techniques
to form predictive models for clinical patient outlook. The accuracy of these novel tech-
niques were statistically tested against linear and logistic regression, the standard medical
prediction methods.
We found that most novel machine learning techniques that we tested were able to de-
liver comparable performance. Both classification and regression algorithms were considered.
Generally, Multi-Layer Perceptrons, Bayesian methods, and Locally Weighted Learning with
Naive Bayes performed best. In most cases, the novel models performed as well as tradi-
tional regression; in some instances they performed even better. Novel regression techniques
delivered better performance more frequently than classification techniques. Models based
on data sets which used feature selection and supervised discretization generally delivered
higher accuracy. In most cases, meta-learning did not improve the accuracy of predictive
models. This is a somewhat surprising result, since meta-learning is designed to overcome
data mining limitations of smaller data sets.
Future work will expand upon the research basis presented here, and should consider
some of the limitations we encountered. First and foremost is attaining a larger patient
data set–whether through accumulating additional UMass patients, or expanding the study
to include additional institutions or research databases like the HCUP National Inpatient
Sample. Continuing to add detail and functionality to the clinical databases will allow for
more thorough studies. New knowledge may be gained in testing a populated database
module for other gastrointestinal cancers or breast cancer. Studies may be conducted on
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the individual modules, and clinical performance may even be tested across different disease
forms.
There are a broad variety of machine learning predictive algorithms which we did not
cover, as well as potential parameter variation for those algorithms we used. There is also
algorithm evaluation to consider. In most cases, our novel classifiers had much higher ac-
curacy than logistic regression. However, very often the classifiers performed only as well
as a ZeroR guess. The way that single target class values dominate these medical data sets
lends itself to predictions for most common class type. This shows simple measurements of
accuracy may not always be the best metric of predictive model quality. Other means of
evaluation may be necessary and should be explored. Furthermore, the algorithms covered
here were based on target class prediction; machine learning to mine association rules and
instance clustering has not yet been considered.
The next step in this research should be to continue adding pancreatic patients to the
clinical database and generating new predictive models. An informal goal set by Dr. Whalen
was to eventually attain classification accuracies of 70% and r-squared values of .50, which
makes it clear that more data and further model refinements are still needed. It is important
to see whether our experimental results hold up or improve across a broader study pop-
ulation. From the clinical database side, the remaining modules will need further testing
and developing. Accumulating clinical data is a critical part of illuminating the design of
these modules; much of the functionality of the pancreatic module was decided upon as
patient data was being entered and research needs became clearer. Further experiments
with neural network based algorithms (MLP, RFB) should be explored in both classification
and regression settings, given their initial accuracy and the broad variety of possible algo-
rithm parameters. In experiments where majority classes dominate (t-stage, malignancy,
etc.), over-sampling techniques should be explored to emphasize the importance of correctly
representing minority classes. Finally, for the more promising predictive models that we’ve
presented here, their performance should be verified against broader pancreatic cancer pa-
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tient sets, or distinct patient sets from other institutions. This will allow us to conclude the
potential of these models for future medical research publication.
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Glossary
Adenocarcinoma: carcinoma which develops within glandular epithelium which typically
behaves in a very malignant fashion, 5
Adjuvant: therapy applied post-surgery, 12
Ampulla of Vater: dilation in the duodenal wall through which the common bile duct and
pancreatic duct empty into the small intestine, 7
Anastomosis: surgically connecting anatomically separate organs to form a continual chan-
nel, 3
Benign: cell growth characterized as not spreading to surrounding tissue, 3
Biopsy: a small sample of tumor tissue taken to evaluate its histologic composition and
malignancy, 6
Cancer: Diseases resulting from uncontrolled cell growth in regions known as neoplasms or
tumors, 3
Carcinogen: Chemical or physical agents which trigger cancer-causing DNA mutations, 3
Carcinoma: cancers arising from epithelial tissue, 3
Celiac axis: artery which originates in the abdominal aorta below the diaphragm, 10
Chemotherapy: systemic or localized application of antineoplastic drugs to destroy or retard
the development of tumor growth, 3
Computed axial tomography (CT or CAT): a three-dimensional internal view of a patient
using a series of sectional x-rays across a common axis, 6
Cyst: closed cavities of glandular epithelium where retained secretions are accumulated,
and may behave in a benign or malignant fashion, 5
245
Cytology: study of cells at a microscopic level, 5
Distal common bile duct: portion of the excretory passage closest to the duodenum which
carries bile from the liver, 7
Duodenum: upper part of the small intestine, which extends from the lower end of the
stomach, 7
ECOG: Eastern Cooperative Oncology Group (ECOG) score for wellbeing, ranges 0-5,
consult Table 2, 4
Endoscopic ultrasound (EUS): ultrasound study generated by a thin, flexible camera passed
through the gastrointestinal tract, 6
Epithelial: related to the epithelium, a membrane of tissue which lines most internal and
external surfaces of the body and organs, 3
Fine needle aspiration (FNA): a biopsy procedure where a sample of cells is obtained ap-
plying suction through a fine needle, 10
G-Stage: refers to grade or differentiation between tumor cells and surrounding normal
cells, ranges from 1 to 4, 5
Gene counseling: series of DNA tests which establish susceptibility of a patient or their
family to certain forms of cancer, 3
Hepatic artery: artery which originates in the celiac artery and supplies the liver with
blood, 10
Histology: the microscopic structure of tumor tissue, 5
Immunotherapy: for tumors, experimental protocol which uses vaccination to trigger an
immune system response which destroys cancerous cells, 3
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In situ: tissue growth confined to the site of origin, 5
Inferior vena cava: vein formed by the union of two iliac veins that transports blood from
the lower limbs and pelvic region, 10
Intraductal papillary mucinous neoplasms: cystic pancreatic tumors which can progress to
cancers (called IPMNs or IPMT’s), 7
Invasion: malignant cell growth into local tissue, 3
Islet cell tumors: see neuroendocrine tumors, 7
Jejunum: middle part of the small intestine, starts at the end of the duodenum, 7
L-Stage: refers to tumor invasion into lymphatic vessels, 0 if absent and 1 if present, 5
Lymph Nodes: small bodies along lymphatic vessels which filter bacteria and foreign bodies,
presence of tumorous tissue within regional lymph nodes is an important prognostic
factor for cancer, 5
M-Stage: refers to metastatis to distant organs and is denoted 0 if absent and 1 if present,
5
Magnetic resonance imaging (MRI): use of magnetic resonance of photons to create a high-
contrast density image, 6
Malignant: cell growth characterized as spreading to surrounding or distant tissue, 3
Metastasis: malignant cell growth to distant sites in the body, 3
N-Stage: refers to regional lymph node involvement, ranges from 0 to 3, 5
Neoadjuvant: therapy applied pre-surgery, 12
Neoplasm: a distinct mass in a tissue or organ, 3
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Neuroendocrine tumors: tumors which grow in nervous or endocrine tissue and tend to
behave in a more indolent fashion than adenocarcinomas, 5
Oncology: branch of medicine which deals with the diagnosis and treatment of malignant
tumors, 3
Palliation: methods intended to relieve cancer symptoms rather than effect a cure, 3
Pancreas: a long gland which sits behind the stomach and secretes digestive juices into the
small intestine and bloodstream, 7
Pancreatic cancer: cancer of the pancreas or periampullary region, 7
Pancreaticoduodenectomy: see Whipple procedure, 12
Periampullary region: area containing the duodenum, distal common bile duct, and ampulla
of Vater, 7
Portal vein: vein that transports blood from the digestive tract, spleen, pancreas, and
gallbladder to the liver, 10
QoL: quality-of-life scores for wellbeing (also known as Karnofsky scores), consult Table 1,
4
R-Stage: refers to tumor growth on margins of surgically excised tissue: 0 for clean margins,
1 for microscopic tumor growth, and 2 for gross tumor growth, 5
Radiotherapy: treatments which use irradiation to destroy cancerous cells, 3
Resection: surgical excision of tumor growth from bodily tissue, 3
Serum study: a blood test, which may include nutritional levels, liver functions, and molec-
ular tumor markers, 6
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Splenic vein: vein generated from several smaller veins which meet at the front surface of
the spleen, 10
Stenting: propping open an anatomical vessel with a metal or plastic stent, 3
Superior mesenteric artery: artery which originates from the upper aorta which supplies
the small intestines and colon, 10
Superior mesenteric vein: vein which begins at the ileum and joins behind the pancreas
with the splenic vein, 10
T-Stage: refers to primary tumor size, ranges from 0 to 4 or ’is’ for in situ growth, 5
Tumor markers: molecular systemic indicators of certain cancer forms, 6
Tumor: a distinct mass in a tissue or organ, 3
Ultrasound: use of ultrasonic waves to create a sonographic visualization a body’s internal
structure, 6
V-Stage: refers to tumor invasion into veins, 0 if absent and 1 if present, 5
Vasculature: blood vessels; penetration of tumors into vasculature can be an important
factor in determining the spread and resectability of the disease, 5
Whipple procedure: most common surgical procedure to treat pancreatic cancer, 12
X-ray: the process of visualizing an internal body image by catching high-energy photons
on photographic film, 6
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